

云康  
YUNKANG

**Yunkang Group Limited**  
**云康集团有限公司**

(Incorporated in the Cayman Islands with limited liability)  
(於開曼群島註冊成立的有限公司)

Stock Code 股份代號 : 2325

2022

Interim Report  
中期報告



# CONTENTS

## 目錄

- 2** Definitions and Glossary of Technical Terms  
釋義及技術詞彙
- 6** Corporate Information  
公司資料
- 9** Financial Highlights  
財務摘要
- 12** Management Discussion and Analysis  
管理層討論及分析
- 35** Corporate Governance and Other Information  
企業管治及其他資料
- 45** Interim Condensed Consolidated Statement of  
Comprehensive Income  
中期簡明綜合全面收益表
- 47** Interim Condensed Consolidated Statement of  
Financial Position  
中期簡明綜合財務狀況表
- 49** Interim Condensed Consolidated Statement of  
Changes in Equity  
中期簡明綜合權益變動表
- 51** Interim Condensed Consolidated Statement of  
Cash Flows  
中期簡明綜合現金流量表
- 53** Notes to the Interim Condensed Consolidated  
Financial Statements  
中期簡明綜合財務報表附註

## Definitions and Glossary of Technical Terms 釋義及技術詞彙

<p>“Audit Committee” 「審核委員會」</p>	<p>指</p>	<p>the audit committee of the Board 董事會審核委員會</p>
<p>“Board” 「董事會」</p>	<p>指</p>	<p>the board of Directors of the Company 本公司董事會</p>
<p>“CAGR” 「複合年增長率」</p>	<p>指</p>	<p>compound annual growth rate 複合年增長率</p>
<p>“China” or “PRC” 「中國」</p>	<p>指</p>	<p>the People’s Republic of China and, except where the context requires, references in this interim report to the PRC or China exclude Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan 中華人民共和國，除文義另有所指外，本中報內對中國的提述不適用於香港、中國澳門特別行政區及台灣</p>
<p>“CLSI” 「CLSI」</p>	<p>指</p>	<p>Clinical and Laboratory Standards Institute, a globally recognized not-for-profit standards development organization with over 24,000 individuals with membership access, whose standards are recognized by laboratories, accreditors, and government agencies around the world to improve medical laboratory testing 臨床實驗室標準化協會，為一間經全球認可的非盈利標準開發機構，擁有逾24,000名會員，其標準獲全球實驗室、認證機構及政府機關認可，以改善醫學實驗室檢測</p>
<p>“Company” or “the Company” 「本公司」</p>	<p>指</p>	<p>Yunkang Group Limited (云康集團有限公司), a company incorporated under the laws of the Cayman Islands with limited liability on July 20, 2018 云康集團有限公司，一家根據開曼群島法律於2018年7月20日註冊成立的有限責任公司</p>
<p>“Controlling Shareholder(s)” 「控股股東」</p>	<p>指</p>	<p>has the meaning ascribed thereto under the Listing Rules, unless the context requires otherwise, refers to Mr. Zhang Yong, YK Development, Daan International, Guangzhou Daan Gene, Da An Gene, Huizekx Limited, Mouduans Limited, Tongfuzc Limited, WJJR Investment Limited, Jin Jun Ying Limited and Source Capital RW Limited 具有上市規則所賦予的涵義，除文義另有所指外，指張勇先生、YK Development、達安國際、廣州達安基因、達安基因、Huizekx Limited、Mouduans Limited、Tongfuzc Limited、WJJR Investment Limited、Jin Jun Ying Limited及Source Capital RW Limited</p>
<p>“Corporate Governance Code” 「企業管治守則」</p>	<p>指</p>	<p>the Corporate Governance Code as set out in Appendix 14 to the Listing Rules 上市規則附錄十四所載企業管治守則</p>



## Definitions and Glossary of Technical Terms

### 釋義及技術詞彙

“Da An Gene”		Daan Gene Co., Ltd. (廣州達安基因股份有限公司), a company limited by shares established in the PRC whose shares are listed on the SME Board of the Shenzhen Stock Exchange (Stock Code: 002030.sz) and one of our Controlling Shareholders
「達安基因」	指	廣州達安基因股份有限公司，一家在中國成立的股份有限公司，其股份在深圳證券交易所的中小板上市（股份代號：002030.sz），為我們的控股股東之一
“Daan International”		Daan International Holdings Limited (達安國際集團有限公司), a company incorporated in Hong Kong with limited liability on September 2, 2008, a subsidiary of Da An Gene and one of our Controlling Shareholders
「達安國際」	指	達安國際集團有限公司，一家於2008年9月2日在香港註冊成立的有限責任公司，為達安基因的附屬公司且為我們的控股股東之一
“Director(s)”		director(s) of the Company
「董事」	指	本公司董事
“FVOCI”		fair value through other comprehensive income
「按公平值計入其他全面收益」	指	按公平值計入其他全面收益
“FVTPL”		fair value through profit or loss
「按公平值計入損益」	指	按公平值計入損益
“Group”		the Company, its subsidiaries and the consolidated affiliated entities as defined in the Prospectus
「本集團」	指	本公司、其附屬公司及招股章程所定義的綜合聯屬實體
“Guangzhou Daan Gene”		Guangzhou Daan Gene Technology Co., Ltd. (廣州市達安基因科技有限公司), a company ultimately controlled by Da An Gene
「廣州市達安基因」	指	廣州市達安基因科技有限公司，一家由達安基因最終控制的公司
“HK\$, “HKD” or “Hong Kong Dollars”		Hong Kong dollars, the lawful currency of Hong Kong
「港元」	指	港元，香港法定貨幣
“Hong Kong”		the Hong Kong Special Administrative Region of the PRC
「香港」	指	中國香港特別行政區
“ICL(s)”		independent Clinical Laboratory(ies), perform(s) tests or procedures to help diagnose and/or treat medical conditions
「獨立臨床實驗室」	指	獨立臨床實驗室，進行檢測或執行程序以協助診斷及／或治療醫療狀況
“Listing Date”		May 18, 2022, the date on which dealings in our Shares first commenced on the Main Board of the Stock Exchange
「上市日期」	指	2022年5月18日，股份首次於聯交所主板開始買賣的日期

## Definitions and Glossary of Technical Terms

### 釋義及技術詞彙

“Listing Rules” 「上市規則」	指	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time 香港聯合交易所有限公司證券上市規則（經不時修訂或補充）
“Main Board” 「主板」	指	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the GEM. For avoidance of doubt, the Main Board excludes the GEM 由聯交所營運的證券交易所（不包括期權市場），獨立於GEM並與其並行運作。為免生疑，主板不包括GEM
“Model Code” 「標準守則」	指	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix 10 to the Listing Rules 上市規則附錄十所載上市發行人董事進行證券交易之標準守則
“PCR” 「PCR」	指	polymerase chain reaction, a method widely used to rapidly make millions to billions of copies of a specific DNA sample 聚合式鹼鏈反應，為一種快速複製數百萬到數十億特定DNA樣本的方法
“Prospectus” 「招股章程」	指	the prospectus of the Company dated May 5, 2022 本公司日期為2022年5月5日的招股章程
“R&D” 「R&D」	指	research and development 研究與開發
“Renminbi” or “RMB” 「人民幣」	指	Renminbi yuan, the lawful currency of the PRC 人民幣元，中國法定貨幣
“Reporting Period” 「報告期間」	指	the six months ended June 30, 2022 截至2022年6月30日止六個月
“SFO” 「證券及期貨條例」	指	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time 香港法例第571章證券及期貨條例（經不時修訂、補充或以其他方式修改）
“Share(s)” 「股份」	指	ordinary share(s) in the share capital of the Company with nominal value of US\$0.000002 each 本公司股本中每股面值0.000002美元之普通股
“Shareholder(s)” 「股東」	指	shareholder(s) of the Company 本公司股東
“Stock Exchange” 「聯交所」	指	The Stock Exchange of Hong Kong Limited 香港聯合交易所有限公司

## Definitions and Glossary of Technical Terms 釋義及技術詞彙

“subsidiary” or “subsidiaries” 「附屬公司」	指	has the meaning ascribed thereto under the Listing Rules 具有上市規則所賦予的涵義
“USD” or “US\$” 「美元」	指	United States dollars, the lawful currency of the United States 美元，美國法定貨幣
“we”, “us” or “our” 「我們」或「我們的」	指	the Company or the Group, as the context requires 本公司或本集團（如文義所指）
“YK Development” 「YK Development」	指	YK Development Limited, a limited liability company duly incorporated in the British Virgin Islands on July 12, 2018 and one of the Company’s Controlling Shareholders YK Development Limited，一家於2018年7月12日在英屬處女群島正式註冊成立的有限責任公司，為本公司的控股股東之一
“%” 「%」	指	per cent 百分比

## Corporate Information 公司資料

### BOARD OF DIRECTORS

#### Executive Director

Mr. Zhang Yong (*Chairman of the Board and Chief Executive Officer*)

#### Non-executive Directors

Ms. Huang Luo (*appointed on August 11, 2022*)

Dr. Guo Yunzhao

Dr. Wang Ruihua (*appointed on July 11, 2022*)

Mr. Zhou Xinyu (*resigned on August 11, 2022*)

Mr. Zhou Weiqun (*resigned on July 11, 2022*)

#### Independent Non-executive Directors

Mr. Yu Shiyou

Mr. Yang Hongwei

Mr. Xie Shaohua

### AUDIT COMMITTEE

Mr. Xie Shaohua (*Chairman*)

Dr. Guo Yunzhao

Mr. Yu Shiyou

### REMUNERATION COMMITTEE

Mr. Yu Shiyou (*Chairman*)

Mr. Zhang Yong

Mr. Xie Shaohua

### NOMINATION COMMITTEE

Mr. Zhang Yong (*Chairman*)

Mr. Yu Shiyou

Mr. Xie Shaohua

### 董事會

#### 執行董事

張勇先生 (*董事長兼行政總裁*)

#### 非執行董事

黃珞女士 (*於2022年8月11日獲委任*)

郭雲釗博士

王瑞華博士 (*於2022年7月11日獲委任*)

周新宇先生 (*於2022年8月11日辭任*)

周偉群先生 (*於2022年7月11日辭任*)

#### 獨立非執行董事

喻世友先生

楊洪偉先生

謝少華先生

### 審核委員會

謝少華先生 (*主席*)

郭雲釗博士

喻世友先生

### 薪酬委員會

喻世友先生 (*主席*)

張勇先生

謝少華先生

### 提名委員會

張勇先生 (*主席*)

喻世友先生

謝少華先生



**JOINT COMPANY SECRETARIES**

Mr. Lin Yingjia  
Ms. Chan Lok Yee

**AUTHORIZED REPRESENTATIVES**

Mr. Zhang Yong  
Ms. Chan Lok Yee

**HONG KONG LEGAL ADVISER**

Kirkland & Ellis  
26/F, Gloucester Tower  
The Landmark  
15 Queen's Road Central  
Hong Kong

**REGISTERED OFFICE**

P.O. Box 31119 Grand Pavilion  
Hibiscus Way  
802 West Bay Road  
Grand Cayman KY1-1205  
Cayman Islands

**HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN THE PRC**

No.6 Lizhishan Road  
Science City  
Huangpu District  
Guangzhou, PRC

**PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

Room 1901, 19/F, Lee Garden One  
33 Hysan Avenue, Causeway Bay  
Hong Kong

**聯席公司秘書**

林穎嘉先生  
陳樂而女士

**授權代表**

張勇先生  
陳樂而女士

**香港法律顧問**

凱易律師事務所  
香港  
皇后大道中15號  
置地廣場  
告羅士打大廈26樓

**註冊辦事處**

P.O. Box 31119 Grand Pavilion  
Hibiscus Way  
802 West Bay Road  
Grand Cayman KY1-1205  
Cayman Islands

**總部及中國主要營業地點**

中國廣州市  
黃埔區  
科學城  
荔枝山路6號

**香港主要營業地點**

香港  
銅鑼灣希慎道33號  
利園一期19樓1901室



## Corporate Information

### 公司資料

#### PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Maples Fund Services (Cayman) Limited  
PO Box 1093  
Boundary Hall  
Cricket Square  
Grand Cayman, KY1-1102  
Cayman Islands

#### HONG KONG SHARE REGISTRAR

Tricor Investor Services Limited  
Level 54, Hopewell Centre  
183 Queen's Road East, Hong Kong  
(change to 17/F, Far East Finance Centre, 16 Harcourt Road,  
Hong Kong with effect from August 15, 2022)

#### INVESTOR RELATIONS

Email: [ir@yunkanghealth.com](mailto:ir@yunkanghealth.com)

#### WEBSITE

<http://www.yunkanghealth.com>

#### STOCK CODE

the Stock Exchange: 2325

#### 主要股份過戶登記處

Maples Fund Services (Cayman) Limited  
PO Box 1093  
Boundary Hall  
Cricket Square  
Grand Cayman, KY1-1102  
Cayman Islands

#### 香港證券登記處

卓佳證券登記有限公司  
香港皇后大道東183號  
合和中心54樓  
(自2022年8月15日起變更為香港夏慤道  
16號遠東金融中心17樓)

#### 投資者關係

電郵：[ir@yunkanghealth.com](mailto:ir@yunkanghealth.com)

#### 網站

<http://www.yunkanghealth.com>

#### 股份代號

聯交所：2325

## Financial Highlights 財務摘要

For the six months ended June 30,  
截至六月三十日止六個月

		2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	Change 變動
Revenue	收益	1,378,656	758,030	81.9%
- Diagnostic outsourcing services	- 診斷外包服務	680,362	483,209	40.8%
- Diagnostic testing services for medical institution alliances	- 為醫聯體提供的診斷檢測服務	650,700	244,449	166.2%
- Diagnostic testing services for non-medical institutions	- 為非醫療機構提供的診斷檢測服務	47,594	30,372	56.7%
Cost of revenue	收益成本	(727,584)	(371,974)	95.6%
Gross profit	毛利	651,072	386,056	68.6%
Profit before tax	除稅前溢利	283,500	181,452	56.2%
Profit for the period	期內溢利	234,761	157,323	49.2%
Profit attributable to owners of the Company:	本公司擁有人應佔溢利：	234,363	156,273	50.0%

For the six months ended June 30,  
截至六月三十日止六個月

		2022 二零二二年 RMB 人民幣 (Unaudited) (未經審核)	2021 二零二一年 RMB 人民幣 (Unaudited) (未經審核)	Change 變動
<b>Earnings per share</b>	<b>每股盈利</b>			
Basic	基本	0.44	0.32	37.5%
Diluted	攤薄	0.44	0.32	37.5%

## Financial Highlights

### 財務摘要

During the Reporting Period, the Group recorded a revenue of RMB1,378.7 million, representing an increase of 81.9% compared to the same period in 2021. This increase was primarily attributable to the rapid growth of the Group's diagnostic testing services during the Reporting Period driven by the promotion of healthcare policy in mainland China and the Group's professional medical diagnostic capabilities, outstanding capabilities of standardization and innovative business models.

During the Reporting Period, the revenue generated from diagnostic outsourcing services reached RMB680.4 million, representing an increase of 40.8% compared to the same period in 2021, primarily due to the performance of key products of the Group maintained robust growth during the Reporting Period; in particular, business in key disease areas such as tumor, infectious diseases and blood diseases were on high-quality development trajectory, driving further growth in revenue from the diagnostic outsourcing services.

During the Reporting Period, the revenue generated from diagnostic testing services for medical institution alliances reached RMB650.7 million, representing an increase of 166.2% compared to the same period in 2021. The increase was primarily due to (i) the increased number of on-site diagnostic centers from 275 as of December 31, 2021 to 350 as of June 30, 2022; and (ii) the further improved services capability and expanded service scope of the on-site diagnostic centers after the preliminary construction and operation, resulting in a rapid growth of the average revenue of unit on-site diagnostic centers. As of June 30, 2022, the semi-annual average revenue of the on-site diagnostic centers was RMB1.9 million (a full-year average revenue of RMB2.2 million in 2021). As a crucial business of the Group, diagnostic testing services for medical institution alliances are constituting an increasing proportion of the Group's total revenue which increased from 32.2% for the six months ended June 30, 2021 to 47.2% for the six months ended June 30, 2022.

報告期內，本集團錄得收益人民幣1,378.7百萬元，較2021年同期增長81.9%。該增加主要由於在中國內地醫療政策的促進及推動下，基於本集團的專業的醫療診斷能力、強大的標準化能力及創新業務模式帶動下，本集團的診斷檢測服務於報告期內呈現快速增長所致。

於報告期間，診斷外包服務錄得收益人民幣680.4百萬元，較2021年同期增長40.8%，主要由於報告期內，本集團重點產品業績保持穩健增長，其中腫瘤、感染性疾病及血液疾病等重點疾病領域業務均呈現高質量發展趨勢，推動診斷外包服務收益規模進一步擴大。

於報告期間，為醫聯體提供的診斷檢測服務錄得收益人民幣650.7百萬元，較2021年同期增長166.2%。該增加主要由於(i)現場診斷中心數量從截至2021年12月31日的275間增長到截至2022年6月30日的350間；及(ii)現場診斷中心經過初期的建設和運營，其服務水準及服務範圍進一步擴大，導致單位現場診斷中心的平均收益增長迅速。截至2022年6月30日，現場診斷中心的半年度平均收益為人民幣1.9百萬元（2021全年的平均收益為人民幣2.2百萬元）。作為本集團的重要業務，為醫聯體提供的診斷檢測服務佔本集團的總收益百分比不斷增加，由截至2021年6月30日止六個月的32.2%增加至截至2022年6月30日止六個月的47.2%。

Diagnostic testing services for non-medical institutions are mainly provided through our outpatient clinics, serving individual customers who are general public and employees of our non-medical institution customers. During the Reporting Period, revenue generated from diagnostic testing services for non-medical institutions reached RMB47.6 million, representing an increase of 56.7% compared to the same period in 2021. The increase was primarily due to the significant increase in demand for COVID-19 tests by individual customers and non-medical institution customers under the ongoing impact of COVID-19 pandemic.

During the Reporting Period, the Group recorded a profit of RMB234.8 million, representing an increase of 49.2% compared to the same period in 2021. The increase was primarily due to an increase of diagnostic testing services for medical institution alliances. Through establishing on-site diagnostic centers, all the member hospitals within the same medical institution alliances can benefit from the standardized and professional diagnostic testing services provided and patients can be referred and directed to the most suitable medical institutions within the medical institution alliances based on their diagnostic testing results. Therefore, diagnostic testing services for medical institution alliances is one of the most effective measures to enhance the diagnostic capacities and service efficiency of medical institution alliances, and can bring positive impact on the Group's profitability on an on-going basis.

為非醫療機構提供的診斷檢測服務主要通過我們的門診診所提供，服務於普通公眾的個人客戶以及我們的非醫療機構客戶的員工。為非醫療機構提供的診斷檢測服務於報告期間錄得收益人民幣47.6百萬元，較2021年同期增長56.7%。該增長主要由於個人客戶及非醫療機構客戶在COVID-19疫情持續影響下對COVID-19檢測的需求大幅增加所致。

報告期內，本集團錄得溢利人民幣234.8百萬元，較2021年同期增長49.2%。該增長主要由於為醫聯體提供的診斷檢測服務增加所致。透過建立現場診斷中心，同一醫聯體內的所有成員醫院均可受惠於所提供的標準化及專業診斷檢測服務，病人可根據其診斷檢測結果轉介及引導至醫聯體內最合適的醫療機構。因此，為醫聯體提供檢測診斷服務是提升醫聯體診斷能力及服務效率的最有效措施之一，可持續為本集團盈利能力帶來正面影響。



## Management Discussion and Analysis 管理層討論及分析

### BUSINESS OVERVIEW

We are a comprehensive and professional medical operation service provider in China, which is committed to focusing on the health needs of customers, providing competitive solutions and services, and creating a happy life for the public. The Group has gradually become a leading medical operation platform through professional medical diagnosis services, strong standardization capabilities, and innovative business model of diagnostic testing services for medical institution alliances. According to Frost & Sullivan, China's medical operation service market is expected to grow from RMB30,694.9 million in 2020 to RMB47,946.1 million in 2025 at a CAGR of 9.3%. The Group's service portfolio mainly includes diagnostic outsourcing services, diagnostic testing services for medical institution alliances and diagnostic testing services for non-medical institutions. During the Reporting Period, the Group's revenue reached RMB1,378.7 million, representing a year-on-year increase of 81.9%, and the overall gross profit margin was 47.2%. The Group's service portfolio maintained high-speed growth, among which the diagnostic testing services for medical institution alliances increased by 166.2% year on year, the diagnostic outsourcing services increased by 40.8% year on year and the diagnostic testing services for non-medical institutions increased by 56.7% year on year.

Diagnostic tests are widely applied in medical treatments as the test results can help identify an individual's medical issues and therefore form the basis for doctors to determine the most suitable treatment plan. Typically, medical institutions conduct certain diagnostic testing items based on their grade, size and other attributes, and consider outsourcing certain diagnostic testing items to qualified testing service institutions based on factors such as quality, cost and efficiency. Starting from 2008, we provide standardized diagnostic testing outsourcing services for medical institutions by performing diagnostic tests and conducting results analysis. Under this business model, medical institutions send test samples to our ICLs for diagnostic testing and issuance of testing reports and pay us diagnostic service fees based on the types and quantities of tests performed at our ICLs.

### 業務概覽

我們是中國一家全面的、專業的醫學運營服務提供者，致力於聚焦客戶的健康需求，提供有競爭力的解決方案與服務，為大眾創造幸福生活。本集團通過專業的醫學診斷服務、強大的標準化能力、為醫聯體提供的診斷檢測服務的創新業務模式，逐漸發展成為醫學運營服務的領先平台。根據弗若斯特沙利文，中國醫學運營服務市場預期將由2020年的人民幣30,694.9百萬元增加至2025年的人民幣47,946.1百萬元，複合年增長率為9.3%。本集團旗下坐擁三大業務線，涵蓋診斷外包服務、為醫聯體提供的診斷檢測服務以及為非醫療機構提供的診斷檢測服務。於報告期內，本集團收益達到人民幣1,378.7百萬元，按年增長81.9%，整體毛利率為47.2%。三大業務線均保持高速增長，其中為醫聯體提供的診斷檢測服務按年增長166.2%，診斷外包服務按年增長40.8%，為非醫療機構提供的診斷檢測服務按年增長56.7%。

診斷檢測被廣泛用於醫學治療，因為檢測結果可幫助識別個人醫療問題，因此為醫生確定最合適的治療方案奠定基礎。通常情況下，醫療機構按照自身的級別、規模等實際情況開展相應的診斷檢測項目，同時根據質量、成本、效率等因素考慮將部分診斷檢測項目外包給合格的檢測服務機構。自2008年以來，我們為醫療機構提供標準化的診斷檢測外包服務，進行診斷檢測並分析結果。在這種業務模式下，醫療機構將檢測樣本送至我們的獨立臨床實驗室進行診斷檢測並出具檢測報告，並根據在我們的獨立臨床實驗室進行的檢測類型及檢測數量向我們支付診斷服務費。

In the past decade, to further improve service quality and efficiency of the healthcare system, the PRC government promulgated a series of promotional and encouraging policies to promote and encourage medical institutions to establish medical institution alliances. According to Frost & Sullivan, the widely used term “medical institution alliance” refers to regional healthcare system consisting of primary, secondary and tertiary medical institutions in a given region, under which medical resources, especially diagnostic capacities, can be shared efficiently, aiming to improve the service quality of primary medical institutions, promote the optimal allocation of medical resources, allocate patients to the appropriate hospitals depending on their medical conditions, and balance the uneven distribution of medical resources and diagnosis demands in China. Driven by relevant policies, many medical institutions establish medical institution alliances to improve their overall diagnostic testing capacities and capabilities. They started to establish diagnostic centers at their sites, especially at those lead hospitals in the medical institution alliances. Normally, there will be one lead hospital, usually being a Class III or Class II hospital, that will take lead of the operation of the medical institution alliance and its on-site diagnostic center and provide testing services. Through the on-site diagnostic center, all the member hospitals can benefit from the standardized and professional diagnostic services by delivering test samples to the corresponding lead hospital. Driven by this, the cumulative number of on-site diagnostic centers in China increased from 396 as of the end of 2016 to 916 as of the end of 2020 at a CAGR of 23.3%, according to Frost & Sullivan. Through this model, medical institutions within the same medical institution alliance do not need to deliver test samples to different outsourced ICLs and may perform diagnostic testing on-site at the corresponding diagnostic center. Further, member hospitals may also enjoy the service of the diagnostic center by sending test samples to the lead hospital and enjoy the same diagnostic service of the lead hospital without separately engaging ICLs. Observing these emerging medical needs, we started to provide diagnostic testing services for medical institution alliances in 2013. Under this model, we provide diagnostic testing services for medical institution alliances at such on-site diagnostic centers in different medical specialties such as pathology, infectious disease and genetic disease. We provide technical supports such as assistance in daily operations, testing equipment and on-site technicians to lead hospitals for establishing and operating on-site diagnostic centers to facilitate the on-site testing services, coordination between lead and member hospitals, and etc. In return, we charge them diagnostic service fees based on the types and quantities of tests performed. Not only are the diagnostic tests conducted at these on-site diagnostic centers, but such collaboration also creates opportunities for our nearby ICLs to provide other diagnostic testing services for the member hospitals within the alliances if the centers are not capable of providing testing services, as per the service and collaboration agreements.

在過去的十年中，為進一步提升醫療體系服務質量和效率，中國政府頒佈了一系列推動及鼓勵政策，鼓勵和促進醫療機構成立醫聯體。根據弗若斯特沙利文，廣為使用的「醫聯體」是指在一定的區域內，由基層、二級及三級醫療機構組成的區域醫療保健體系，其可有效共用醫療資源，尤其是診斷能力，旨在提高基層醫療機構的服務質量，促進醫療資源的最佳分配，根據患者病情將其分配至適當的醫院，平衡中國醫療資源與診斷需求的分配不均。在相關政策的驅動下，許多醫療機構建立聯盟以提高彼等的整體診斷檢測容量及能力，彼等開始在其場地內，特別是在醫聯體內的龍頭醫院內建立診斷中心。一般而言，會有一間龍頭醫院（通常為三級或二級醫院），負責醫聯體及現場診斷中心的運營及提供檢測服務。通過現場診斷中心，所有成員醫院均可透過向對應的龍頭醫院提供檢測樣本，從標準化及專業的診斷服務中受益。根據弗若斯特沙利文，受此驅動，中國的現場診斷中心的累計數量由截至2016年底的396間增至截至2020年底的916間，複合年增長率為23.3%。透過此模式，同一醫聯體內的醫療機構無需將檢測樣本送至不同的外包獨立臨床實驗室，而可於相應的診斷中心進行現場診斷檢測。此外，成員醫院亦可透過將檢測樣本送至龍頭醫院享受診斷中心服務，無需單獨委聘獨立臨床實驗室即可享受龍頭醫院相同的診斷服務。鑒於該等新興醫療需求，我們於2013年開始為醫聯體提供診斷檢測服務。在這種業務模式下，我們為相關現場診斷中心的醫聯體在病理學、感染病及遺傳病等不同的醫療專科領域提供診斷檢測服務。我們為龍頭醫院現場診斷中心的建立及營運提供技術支持，如在日常營運、檢測設備及現場技術人員方面提供協助，以促進現場檢測服務以及龍頭醫院及成員醫院之間的協作等。在費用收取方面，我們根據在現場診斷中心已進行的檢測類型及數量向其收取診斷服務費。我們不僅於該等現場診斷中心進行診斷檢測，倘該等中心無法按服務及合作協議提供檢測服務，則該等合作亦為我們鄰近的獨立臨床實驗室向醫聯體內的成員醫院提供其他診斷檢測服務提供機會。



## Management Discussion and Analysis

### 管理層討論及分析

We believe diagnostic expertise and standardized testing capabilities are crucial to our success. We are constantly adopting new technologies for testing, encompassing all major clinical laboratory technology platforms. We have a number of ICLs in China that hold both ISO15189 and College of American Pathologists certifications. We are the only execution partner of healthcare business of CLSI with the joint objectives to improve the overall performance of clinical laboratories in China. We are also the only branch office of CLSI in China which enable us to enhance our diagnostic capability in accordance with international standards and demonstrating the recognition of our diagnostic testing capabilities.

In conclusion, as a leading medical operation service platform in China, we have established six operation modules (including overall business planning, quality control, hierarchical diagnosis and treatment, marketing, smart logistics and supply chain) and seven technology platforms (including immunological detection, mass spectrometry, PCR, high-throughput sequencing, liquid chip, ultra-micro pathological morphology and digital pathology remote diagnosis) and have 1,500 medical technicians to offer continuous support to quality clinical diagnostic services and operation in dozens of independent laboratories, including central laboratories, provincial comprehensive laboratories and rapid response laboratories, covering more than 3,600 medical institutions and 350 on-site diagnostic centers in medical institution alliances covering 31 provinces, cities and autonomous regions in China.

#### Business Model

Building on the diagnostic expertise and the established healthcare services network, the Group's service portfolio mainly includes the following:

- *Diagnostic outsourcing services*

The Group offers diagnostic outsourcing services to hospitals, other medical institutions and public institutions. Hospitals need to conduct diagnostic testing on patients' test samples, which, considering the high volume of patients' test samples overall for various test types, can be time- and cost-consuming. As for other medical institutions and public institutions, they do not have the required capabilities to conduct all diagnostic testing items themselves. For these aforementioned reasons, these institutions generally conduct certain diagnostic testing items based on their grade, size and other attributes, and consider outsourcing certain diagnostic testing items to qualified testing service institutions based on factors such as quality, cost, and efficiency.

我們相信，診斷專業知識及標準化檢測能力對我們的成功至關重要。我們不斷採用新技術進行檢測，檢測技術涵蓋所有主要臨床實驗室技術平台。我們旗下擁有全國多家同獲ISO15189和美國病理學院雙認可的一流獨立實驗室。同時，我們是CLSI醫療業務的唯一執行夥伴，共同目標是為提高中國臨床實驗室的整體表現，亦是中國唯一的CLSI分支機構，這使我們能夠根據國際標準提升我們的診斷能力，並促使我們的診斷檢測能力獲得認可。

綜上所述，作為中國醫學運營服務市場的領先平台，我們建立六大運營模組（包括整體業務規劃、品質控制、分級診療、行銷、智慧物流及供應鏈）和七大技術平台（包括免疫檢測、質譜、PCR、高通量測序、液態芯片、超微病理形態學及數字病理遠程診斷），擁有超過1,500名醫療技術人員，持續支持旗下包括中心實驗室、省級綜合實驗室、區域快速反應實驗室等數十家獨立實驗室，覆蓋全國31個省市及自治區的3,600多家醫療服務機構，以及350個醫聯體內現場診斷中心的高品質臨床診斷服務及運營。

#### 業務模式

基於診斷專業知識及已建立的醫療服務網路，本集團的服務組合主要包括以下：

- *診斷外包服務*

本集團為醫院、其他醫療機構及公共機構提供診斷外包服務。醫院需要對患者的檢測樣本進行診斷檢測，而由於多種檢測類型的整體患者檢測樣本量較大，診斷檢測可能會耗時耗資。其他醫療機構及公共機構並不具備自行進行所有診斷檢測項目所需的能力。由於上述原因，該等機構通常按照自身的級別、規模等實際情況開展相應的診斷檢測項目，同時根據質量、成本、效率等因素考慮將部份診斷檢測項目外包給合格的檢測服務機構。

## Management Discussion and Analysis 管理層討論及分析

The Group operates dozens of independent laboratories, including central laboratories, provincial comprehensive laboratories and regional rapid response laboratories nationwide, covering all major clinical testing technology platforms (such as immunoassay, mass spectrometry, PCR, high-throughput sequencing, liquid chip, ultrastructural pathology and digital pathology remote diagnosis), with an increasing number of more than 2,000 testing items. These laboratories aim at offering diagnostic testing services to the Company's customers in their located regions or neighbouring provinces and cities, and supporting the Group's on-site diagnostic centers within medical institution alliances in the local or neighbouring provinces and cities when necessary.

- *Diagnostic testing services for medical institution alliances*

We offer diagnostic testing services for medical institution alliances. The first key step of these services is to assist in the establishment of an on-site diagnostic center at the lead hospital. Through the on-site diagnostic centers, medical institutions have the opportunity to build up their diagnostic capacities in a more efficient way as the test samples collected at the medical institutions do not need to be delivered to the ICLs for testing. Instead, the medical institutions can complete the testing at these diagnostic centers on-site. Relying on our services, member hospitals can offer standardized diagnostic testing services to patients, and, with our issued diagnostic testing reports, better understand the characteristics and conditions of the patients and direct the patients to the most suitable medical institution within the alliances that has the most experiences in handling similar patients.

本集團在全國範圍內運營包括中心實驗室、省級綜合實驗室、區域快速反應實驗室在內的數十家獨立實驗室，包含所有主要的臨床檢驗技術平台（如免疫檢測、質譜、PCR、高通量測序、液態芯片、超微病理形態學及數字病理遠端診斷等），檢測項目超過2,000項並不斷增加。各實驗室的目標是為其所在地區或鄰近省份及城市的客戶提供診斷檢測服務，並在必要時支援本集團在當地或鄰近省份及城市醫聯體的現場診斷中心。

- *為醫聯體提供的診斷檢測服務*

我們為醫聯體提供診斷檢測服務。該等服務的第一個關鍵步驟是在龍頭醫院協助建立現場診斷中心。通過現場診斷中心，醫療機構有機會以更有效率的方式提高彼等的診斷能力，因其無需再將收集的檢測樣本送至獨立臨床實驗室進行檢測，而可原地於該等診斷中心完成檢測。憑藉我們的服務，成員醫院可為患者提供標準化的診斷檢測服務，並通過我們已發出的診斷檢測報告，更好地了解患者的病症及病情，並將患者引導至醫聯體中最合適的醫療機構，該等醫療機構在治療類似患者方面的經驗最豐富。




## Management Discussion and Analysis 管理層討論及分析

The Group usually assists lead hospitals in relevant regions to establish on-site diagnosis centers in four main types (i.e. pathology, infectious disease, genetic disease and routine diagnostic tests), and provides lead hospitals with comprehensive quality solutions including testing technologies, professional technicians, core technical equipment, standardized product quality control system, medical cold chain logistics and professional marketing, so as to promote the overall technical level and operational efficiency of the medical institution alliance in the region.

The following diagram illustrates our role and value propositions in our diagnostic testing services for medical institution alliances.

本集團通常在四個主要領域（即病理學、感染病、遺傳病及常規診斷檢測）協助區域內的龍頭醫院建立現場診斷中心，為龍頭醫院提供包括檢測技術、專業技術人員、核心技術設備、標準化品質控制系統、醫學冷鏈物流及專業市場推廣等全方位高品質的綜合解決方案，推動區域內醫聯體整體技術水準及運營效率。

下圖列示我們在醫聯體內診斷檢測服務中的角色及價值主張。



## Management Discussion and Analysis 管理層討論及分析

The on-site diagnostic center is normally located at the lead hospital. Member hospitals within the same medical institution alliance may also use the diagnostic capacities of the center, as they will also deliver their test samples to the diagnostic center for testing. Therefore, our diagnostic testing services for medical institution alliances assist hospitals to better manage their diagnostic operation by centralizing and utilizing their resources to enhance the diagnostic capacities of the whole medical institution alliance.

As an industry norm, although the service and collaboration agreements for the on-site diagnostic centers normally do not contain an exclusivity clause, medical institutions will normally engage the medical operation service providers such as us to perform other types of diagnostic tests that these diagnostic centers are not capable of performing themselves. Therefore, if the centers are not capable of performing certain diagnostic tests, they may utilize diagnostic capacity of our nearby ICLs. In return, we charge medical institutions for diagnostic testing services based on the number of diagnostic tests performed (either by the on-site diagnostic centers or by our ICLs).

To facilitate the operation of the on-site diagnostic centers, we provide a wide range of technical supports. Such technical supports only create channels for generating revenue from diagnostic testing services but do not generate revenue directly from themselves. We provide these services integrated as a service package to medical institutions based on their needs. This service package mainly include technical supports and daily assistance for operations, which is important because many of the medical institutions do not have sufficient or expertise in diagnostic testing and therefore need the support of medical operation service providers in relation to the provision of testing equipment, staff training, on-site testing expertise and establishment of standardized procedures and protocols, as well as assistance in the logistics of test samples. As a result of our involvement, we are also responsible for issuing diagnostic testing reports to the lead hospital.

現場診斷中心通常位於龍頭醫院。同一醫聯體內的成員醫院亦可利用該等中心的診斷能力，將其檢測樣本送至診斷中心進行檢測。因此，我們就醫聯體的診斷檢測服務協助醫院透過集中利用其資源提升整個醫聯體的診斷能力，更好地管理其診斷業務。

作為行業規範，儘管就現場診斷中心簽訂的服務及合作協議一般不包含排他性條款，醫療機構通常會委聘醫學服務提供商（例如本集團）進行該等診斷中心無法自行進行的其他類診斷檢測。因此，倘該等中心無法進行若干診斷檢測，其或會利用我們附近的獨立臨床實驗室的診斷能力。作為回報，我們根據進行的診斷檢測數量（由現場診斷中心或我們的獨立臨床實驗室進行）向醫療機構收取診斷檢測服務費。

為方便現場診斷中心的運作，我們提供廣泛的技術支持。該等技術支持僅為診斷檢測服務產生收益的渠道，而非自其自身直接產生收益。我們提供的該等服務以服務組合形式進行整合，按需求提供予醫療機構。此服務組合主要包括技術支持及日常運營協助，由於許多醫療機構缺乏足夠的診斷檢測專業知識，因此需要醫學運營服務提供商在提供檢測設備、員工培訓、現場檢測專業知識及建立標準化程序及方案，以及協助檢測樣本的物流服務方面提供支持，此服務組合因而尤為重要。由於我們的參與，我們亦負責向相關龍頭醫院出具診斷檢測報告。

## Management Discussion and Analysis

### 管理層討論及分析

Leveraging the continuously development of on-site diagnostic centers networks of medical institution alliance, the diagnostic testing services for medical institution alliances witnessed rapid growth during the recent years. As of December 31, 2018, 2019, 2020 and 2021 and as of June 30, 2022, we assisted in establishing and operating 79, 132, 199, 275 and 350 on-site diagnostic centers, respectively, far exceeding the market's average growth. Meanwhile, we currently have nearly 90 ongoing projects on on-site diagnostic centers with hospitals which have yet to commence operation as the relevant hospitals are currently carrying out internal approval procedures. We believe that the continuous expansion of the network of on-site diagnostic centers will enable us to acquire a larger market share.

- *Diagnostic testing services for non-medical institutions*

The Group offers diagnostic testing services for non-medical institutions which mainly include personalized diagnostic testing, medical report consultation services and hospital referral services. Through these services, the Group provides basic consultation based on the diagnostic testing report we issued and refers those patients to the suitable hospitals for future treatment that it considers appropriate. The Group primarily provides health management services offline where it conducts basic diagnostic testing and health checkup for individual customers at its outpatient clinic or locations requested by its customers.

#### Our Competitive Advantage

We believe that the following strengths differentiate us from our competitors, have contributed to our historical success and will drive our future growth: (i) we are a medical operation service provider in China, strategically focused on diagnostic testing to capture significant market opportunities; (ii) we are an expertise-driven platform in China, empowering hospitals to build up international-standard testing systems; (iii) we provide diagnostic testing services for medical institution alliances enabling scalable and rapid business growth; (iv) we established a loyal customer network with broad nationwide coverage; and (v) we have an experienced senior management and high caliber team.

經過我們持續發展醫聯體內的現場診斷中心網路建設，為醫聯體提供的診斷檢測服務於近幾年增長快速。截至2018年、2019年、2020年及2021年12月31日及截至2022年6月30日，我們分別協助建立及運營79間、132間、199間、275間及350間現場診斷中心，遠超市場平均增速。同時，我們目前還有近90個正在進行的醫院的現場診斷中心項目，由於相關醫院目前正進行內部審批流程，故該等診斷中心尚未開始運營。我們相信繼續拓展現場診斷中心網絡，將使我們能獲得更大的市場份額。

- *為非醫療機構提供的診斷檢測服務*

本集團為非醫療機構提供診斷檢測服務，主要包括個性化診斷檢測、醫療報告諮詢服務及醫院轉診服務。透過該等服務，本集團根據其出具的診斷檢測報告提供基本諮詢服務，並將該等患者轉介至合適的醫院進行其認為適當的後續治療。本集團主要提供線下健康管理服務，於門診所或客戶要求的地點為個人客戶進行基本診斷檢測及健康體檢服務。

#### 我們的競爭優勢

我們相信下列優勢使我們從競爭對手中脫穎而出，該等優勢對我們的歷史成就作出貢獻，並將推動我們未來的增長：(i)我們是中國的一家醫學運營服務提供商，戰略上專注於診斷檢測，以獲取巨大的市場機遇；(ii)我們是中國一家專業驅動型平台，賦能醫院建立國際標準的檢測體系；(iii)我們為醫聯體提供診斷檢測服務，實現業務的規模化及快速增長；(iv)我們建立了覆蓋全國的忠誠客戶網絡；及(v)我們擁有經驗豐富的高級管理層及高質素團隊。



### INDUSTRY OVERVIEW

Under the guidance of observing the general strategy of “Guarding against the Imported Cases and Preventing the Resurgence of Domestic Break” (外防輸入、內防反彈) and the general approach of “Dynamic zero-COVID” (動態清零), China has made epidemic prevention and control a regular measure. With the efficient coordination of epidemic prevention and control as well as economic and social development, the effects of various policies and measures to strongly maintain stability in the economy play out successively, and China’s economy is expected to continue to rebound and remain to run within a reasonable range. Since the outbreak of the COVID-19 epidemic in 2020, China’s medical and health system has faced enormous challenges, and overall economic and social stability is directly hinged on strong and effective protection of the lives and health of the people.

In the post-epidemic era, with the continuous boosting of society’s guard against viruses and awareness of health, the development of China’s healthcare service market has sped up. Overall, the year 2022 has witnessed continuous and strengthening support on the policy front: the 2022 Government Work Report 《2022 年政府工作報告》 has pointed out the necessity to continue to promote hierarchical diagnosis and treatment and enhance the order of medical treatment, expedite the building of national and provincial regional medical centers, promote the extension of quality medical resources to cities and counties and improve the capacity of primary disease prevention and treatment, so that the people can access better healthcare services nearby.

The Outline of the Fourteenth Five-Year Plan for the National Economic and Social Development and the Long-Range Objectives Through the Year 2035 of the People’s Republic of China 《中華人民共和國國民經濟和社會發展第十四個五年規劃和 2035 年遠景目標綱要》 released in March 2022 has pointed out that deepening the reform of the medical and health system should be the focus, and clearly specified that reform tasks such as the establishment of a modern hospital management system, expansion of the capacity of quality medical resources and balanced regional presence should be expedited. It has also clearly specified that the capacity of public health services should be significantly enhanced, and the quality of medical and health services should achieve continuous improvement by 2025. The capacity of primary medical and health services should be continuously improved, the comprehensive and full-cycle health services system should be gradually enhanced, and the landscape of hierarchical diagnosis and treatment should be gradually established.

### 行業概覽

在國家堅持「外防輸入、內防反彈」總策略和「動態清零」總方針的指導下，中國疫情防控進入常態化階段。隨著高效統籌疫情防控和經濟社會發展，有力推進穩經濟的各項政策措施效應不斷顯現，我國經濟有望繼續回升、保持在合理區間。自2020年疫情爆發以來，中國醫療衛生體系面臨巨大挑戰，有力有效保障人民群眾生命健康，直接關係經濟社會大局穩定。

後疫情時代，隨著全社會對病毒的防範和健康意識的不斷提升，中國醫療保健服務市場加速發展。2022年，政策端整體延續了支持力度，並不斷增強：《2022年政府工作報告》中指出要持續推進分級診療和優化就醫秩序，加快建設國家、省級區域醫療中心，推動優質醫療資源向市縣延伸，提升基層防病治病能力，使群眾就近得到更好醫療衛生服務。

2022年3月發佈的《中華人民共和國國民經濟和社會發展第十四個五年規劃和2035年遠景目標綱要》指出要將深化醫藥衛生體制改革作為重點，明確加快建立現代醫院管理制度、加快優質醫療資源擴容和區域均衡佈局等改革任務。明確到2025年，公共衛生服務能力要顯著增強，醫療衛生服務品質持續改善。基層醫療衛生服務能力不斷提升，全方位全週期健康服務體系逐步健全，分級診療格局逐步構建。



## Management Discussion and Analysis

### 管理層討論及分析

- In terms of public health protection, measures are to promote the coordinated development of county-level disease prevention and control institutions and county-level medical alliances, and to improve the laboratory testing capacity of medical and health institutions. Medical and health institutions of high standards should play the role of national bases for the prevention and treatment of major infectious diseases and boost the capacity of promoting outward extension. Other measures include the improvement of network for treatment of infectious diseases in prefectural cities, the advancement of the ability of county hospitals in the testing and treatment of infectious diseases and the enhancement of the capability of primary medical and health institutions in the prevention and control of infectious diseases.
- In terms of strengthening support and assurance for national health, measures are to speed up the establishment of the hierarchical diagnosis and treatment system, to strengthen the grid layout and management of medical groups in cities, to accelerate the promotion of comprehensive medical reform in counties, and to promote the establishment of compact medical and health alliances in counties and the development of specialist alliances and telemedicine collaboration networks.
- 在公共衛生防護方面，推動縣級疾病預防控制機構與縣域醫共體協同發展，提高醫療衛生機構實驗室檢測能力。依託高水準醫療衛生機構，發揮國家重大傳染病防治基地作用，提高輻射帶動能力。進一步完善地市級傳染病救治網路，提高縣級醫院傳染病檢測和診治能力。強化基層醫療衛生機構傳染病防控能力。
- 在強化國民健康支撐與保障方面，加快建設分級診療體系，加強城市醫療集團網絡化佈局管理，加快推動縣域綜合醫改，推進緊密型縣域醫共體建設，推進專科聯盟和遠程醫療協作網發展。

With the coming into effect successively of a series of supportive policies and an array of subsequent national policies for promoting a stable economy, the healthcare service market in China enjoys tremendous growth potential. According to the Frost & Sullivan Report, from 2016 to 2020, the total healthcare service market in China increased from RMB3,316.6 billion to RMB4,869.0 billion, representing a CAGR of 10.1%. However, the total healthcare expenditure as a percentage of gross domestic product (GDP) in China is relatively low compared with that of developed countries. Going forward, the total healthcare service market in China is expected to reach RMB7,519.6 billion by 2025, which represents a CAGR of 9.1% from 2020 to 2025.

基於一系列政策的支持及國家後續推動穩經濟一攬子政策進一步生效，中國醫療保健服務市場蘊含巨大增長潛力。弗若斯特沙利文報告，於2016至2020年，中國醫療保健服務市場總額由人民幣33,166億元增加至人民幣48,690億元，複合年增長率為10.1%。然而，中國醫療保健開支總額佔其國內生產總值(GDP)的百分比與發達國家相比相對較低。未來，中國醫療保健服務市場總規模預計將於2025年達至人民幣75,196億元，即2020年至2025年的複合年增長率為9.1%。

#### Medical Operation Service Market in China

Medical operation services primarily relate to diagnostic testing services offered to medical institutions which can be divided into diagnostic outsourcing services and diagnostic testing services for medical institution alliances. With the enactment of supportive policies and growing public awareness of healthcare in China, medical operation service market in China has experienced rapid growth, and is expected to increase from RMB30,694.9 million in 2020 to RMB47,946.1 million in 2025 at a CAGR of 9.3%.

#### Diagnostic Testing Services for Medical Institution Alliances Market in China

Since 2017, as part of the healthcare reform, the PRC government has established a series of policies to support the local integration of China's healthcare system in the context of the hierarchical diagnosis and treatment system. Medical institution alliances refer to regional healthcare systems consisting of primary, secondary and tertiary medical institutions, under which medical resources can be shared efficiently, aiming to improve the service quality of primary medical institutions, promote the optimal allocation of medical resources, allocate patients to the appropriate hospitals depending on their medical conditions, and balance the uneven distribution of medical resources and diagnosis demands in China. In particular, medical institutions are encouraged to strengthen regional medical resources sharing by setting up diagnostic centers to provide services of the same quality for themselves and promote mutual recognition of diagnostic results. As such, medical institution alliances can help the hierarchical diagnosis and treatment system improve its overall medical service capacity. In recent years, the PRC government has promulgated a series of regulations to promote the development of medical institution alliances, including the Guidance on Promoting Medical Institution Alliances in China (關於推進醫療聯合體建設和發展的指導意見) issued by the State Council in April 2017 and the Interim Measures on Medical Institution Alliance Management (醫療聯合體管理辦法(試行)) issued by the National Health Commission of the PRC in July 2020 (the "Measures"). Pursuant to the Measures, medical institutions are encouraged to join medical institution alliances to enhance the hierarchical diagnosis and treatment system in China.

#### 中國醫學運營服務市場

醫學運營服務主要與向醫療機構提供的診斷檢測服務有關，該等服務可分為診斷外包服務及為醫聯體提供的診斷檢測服務。隨著中國利好政策的出台以及公眾醫療保健意識的增強，中國的醫學運營服務市場快速發展，預期將由2020年的人民幣30,694.9百萬元增加至2025年的人民幣47,946.1百萬元，複合年增長率為9.3%。

#### 中國醫聯體的診斷檢測服務市場

自2017年以來，作為醫療改革的一部分，中國政府制定了一系列政策，以在分級診療制度的背景下支持中國醫療體系的本地整合。醫聯體是指由基層、二級及三級醫療機構組成的區域性醫療體系，在此體系下，醫療資源可有效共用，其旨在提高基層醫療機構的服務質量，促進醫療資源的最佳分配，分配患者到適當的醫院（視乎其病情）並解決中國醫療資源與診斷需求的分配不均衡情況。尤其是，鼓勵醫療機構加強區域醫療資源共用，設立診斷中心為自身提供相同的優質服務，促進診斷結果相互認可。因此，醫聯體可協助分級診療制度改善其整體醫療服務能力。近年來，中國政府已頒佈一系列法規以促進醫聯體的發展，包括國務院於2017年4月發佈的《關於推進醫療聯合體建設和發展的指導意見》及中國國家衛生健康委員會於2020年7月發佈的《醫療聯合體管理辦法(試行)》(「辦法」)。相關辦法鼓勵醫療機構加入醫聯體以鞏固中國的分級診療制度。

## Management Discussion and Analysis 管理層討論及分析

With the introduction of supportive policies (including the Guidance on Promoting Medical Institution Alliances in China by the State Council in April 2017, the Implementation Methods to Advance COVID-19 Nucleic Acid Tests issued by the Disease Protection Bureau of China Center for Disease Control and Prevention in June 2020; the Interim Measures on Medical Institution Alliance Management issued by the National Health Commission in July 2020; and Notice on Continuous Improvement in the Management of Clinical Use of Antimicrobial Drugs issued by National Health Commission in July 2020) and the growing awareness of healthcare among the population, the total market size of diagnostic testing services for medical institution alliances in China shows an increasing trend. In 2020, the market size of diagnostic testing services for medical institution alliances in China was RMB2,200.9 million, compared with a market size of RMB617.7 million in 2016, representing a CAGR of 37.4% from 2016 to 2020. The market size is expected to grow to RMB5,903.4 million in 2025, representing a CAGR of 21.8% from 2020 to 2025.

### Business Outlook and Development Strategy

The Company was successfully listed on the Stock Exchange on May 18, 2022, which provided the Group with a good opportunity to develop in the future. With the help of the capital market, the Group will consolidate its leading position in the medical operation service industry in the PRC. In order to achieve the Group's long-term goal of helping optimize medical resources allocation and accelerate industry development, the Group adopts active development strategies, including but not limited to the following:

#### *Continue to expand and deepen our medical institution alliance network*

The Group plans to ramp up efforts to expand its diagnostic testing services for medical institution alliances business. As at June 30, 2022, there were 350 ongoing projects on on-site diagnostic centers with hospitals. At the same time, the Group currently has nearly 90 ongoing projects on on-site diagnostic centers with hospitals which have yet to commence operation as the relevant hospitals are currently carrying out internal approval procedures. Generally the completion of the internal approval procedures by the medical institutions will take two to three months. For certain hospitals that do not currently have diagnostic capacities, the Group intends to help them improve laboratories and help them manage and operate such laboratories. Over the next few years, the Group plans to primarily focus on pathology, genetic and infectious disease laboratories for medical institution alliances and further improve their precision medicine capability.

隨著利好政策的出台（包括2017年4月國務院發佈的《關於推進醫療聯合體建設和發展的指導意見》，中國疾病預防控制中心疾病防疫局2020年6月發佈的《加快推進新冠病毒核酸檢測實施辦法》；國家衛生健康委於2020年7月發佈的《醫療聯合體管理辦法（試行）》；及國家衛生健康委員會於2020年7月發佈的《關於進一步加強抗菌藥物臨床應用管理工作的通知》）以及公眾對醫療保健意識的增強，中國醫聯體診斷檢測服務的總市場規模呈現日益增長的趨勢。於2020年，中國醫聯體診斷檢測服務的市場規模為人民幣2,200.9百萬元，而2016年的市場規模為人民幣617.7百萬元，2016年至2020年的複合年增長率為37.4%。到2025年，中國的市場規模預期將增長至人民幣5,903.4百萬元，2020年至2025年的複合年增長率為21.8%。

### 業務展望及發展策略

本公司於2022年5月18日在聯交所成功上市，為本集團的未來發展提供了良好機遇。本集團會憑藉資本市場鞏固在中國醫學運營服務行業的領先地位。為實現本集團的長期目標，即助力優化醫療資源分配並加速行業發展，本集團採取積極發展策略，包括但不限於以下各項：

#### *繼續擴展及深化我們的醫聯體網絡*

本集團計劃加大力度擴大為醫聯體提供的診斷檢測服務業務。於2022年6月30日，共有350個與醫院正在進行的現場診斷中心項目。同時，本集團目前還有近90個正在進行的醫院的現場診斷中心項目，由於相關醫院目前正進行內部審批流程，故這些診斷中心尚未開始運營。一般來說，該等醫療機構完成內部審批程序需要耗時兩至三個月。對於目前並無診斷能力的若干醫院，本集團擬協助其改善實驗室，並協助其管理及營運該等實驗室。在未來數年內，本集團計劃主要專注於醫聯體病理、遺傳病及感染病實驗室，進一步提升其精準醫療能力。



## Management Discussion and Analysis 管理層討論及分析

The Group also plans to establish more sales and customer service representative offices to serve its customers. The Group believes that increasing the coverage of its representative office network will enable its sales and marketing and after-sales customer service personnel to more closely interact with customers and develop stronger and deeper business relationships. The Group intends to conduct more site visits and create more frequent feedback and communication opportunities with customers. Through closer and more frequent communication, the Group hopes to better understand customer needs and design and provide solutions to meet those needs, and in turn, maintain our market position.

### *Continue to upgrade and enhance our operational capabilities*

The Group believes continuous upgrade and enhancement of our operational capabilities as a platform of medical operation services is critical for us to improve customer experience and plan to focus on the following areas: (i) to enhance local service capabilities. The Group plans to strategically develop small-scale self-operated ICLs in select regions and areas in China near the Group's major customers or based on market needs to better provide timely services for customers; (ii) to digitalize diagnostic testing. The Group aims to digitalize its testing services and plans to develop technical and operating systems to support its operations; (iii) to pursue potential acquisition and investment opportunities. In order to further enhance its operational capabilities, the Group may consider to acquire or invest in companies that have synergistic businesses with it, such as upstream companies engaged in advanced diagnostic techniques, molecular biology, biotechnology and their clinical applications; and (iv) to upgrade the Group's headquarters. To meet the needs of its growing business, the Group plans to upgrade our headquarters in Guangzhou.

Through the measures mentioned above, the Group believes it can continue to increase its market share in the future. The Group also plans to deepen its penetration in the areas where the current market leader does not have sufficient presence, and gradually expand to other areas in China to capture a larger market share in the future.

本集團亦計劃設立更多銷售及客戶服務代表辦事處，以服務客戶。本集團相信，擴大代表辦事處網絡的覆蓋範圍將令其銷售及市場營銷以及售後客戶服務人員能夠與客戶進行更緊密的互動，並建立更牢固、更深厚的業務關係。本集團擬進行更多實地訪問，經常向客戶提供反饋意見並保持溝通。透過更緊密、更頻繁的溝通，本集團希望更深入瞭解客戶需求並設計及提供滿足該等需求的解決方案，從而保持我們市場地位。

### *繼續升級及提高我們的營運能力*

本集團認為作為一個醫學運營服務平台，運營能力的持續升級及提高非常重要，有助我們改善客戶體驗並計劃專注於以下領域：(i)提高本地服務能力。本集團計劃在中國臨近本集團主要客戶或基於市場需要的選定區域及地區策略性地建立小型自營獨立臨床實驗室，以更好地為客戶提供及時的服務；(ii)數字化診斷檢測。本集團旨在以數字化方式提供檢測服務，亦計劃開發支援其運營的技術及操作系統；(iii)尋求潛在收購及投資機遇。為進一步提升運營能力，本集團或會考慮收購或投資與其有協同業務的公司，如從事先進的診斷技術、分子生物學、生物技術及其臨床應用的上游公司；及(iv)本集團總部升級。為滿足不斷增長的業務需求，本集團計劃升級位於廣州的總部。

透過上述措施，本集團相信日後可繼續增加市場份額。本集團亦計劃深化在目前市場領導者影響力不足的地區的滲透，並逐步擴展至中國其他地區，以爭取未來更大的市場份額。



## Management Discussion and Analysis

### 管理層討論及分析

#### *Expand our portfolio of diagnostic capabilities*

The Group plans to expand its portfolio of diagnostic capabilities, in particular, for tumors, genetic diseases, infectious diseases and pharmacogenetics. With respect to these areas, the Group plans to continue to enhance its diagnostic testing technologies, upgrade its equipment and recruit more personnel as appropriate to support our expansion. As the Group expands its diagnostic capabilities, we plan to market its services to more non-medical institution customers, such as corporations and government agencies, enhancing its ability to provide omni-scenario medical operation services for customers. Through the continued expansion of its capabilities, the Group also endeavors to work with hospitals to provide precision medicine solutions to patients.

The Group believes that precision medicine will be a growing trend in the healthcare industry as more and more patients seek customized medical solutions. Diagnostic testing is crucial to enhance precision medicine as accurate diagnostic testing will enable physicians to understand the characteristics of the patients to customize their treatment plan. Leveraging its experience and market leadership in diagnostic testing, the Group intends to be a first mover in capturing this industry opportunity.

#### *Continue to attract and train our talent pool*

The Group plans to continue to attract and train up talented and experienced personnel to support its expanding business. In particular, the Group plans to focus on technical and medical personnel, as well as management personnel, whom the Group believes are the key backbone of its business. The Group intends to create an employee promotion and advancement system with a grade structure and corresponding compensation scheme. The Group also may put in place incentive schemes to motivate and align the interests of its employees in the future. The Group will also implement training programs for different departments to enhance their professional and technical knowledge. The Group also plans to invest more in Yunkang Medical and Health Management College program to attract and cultivate more talents.

#### *擴大我們的診斷能力組合*

本集團計劃擴大診斷能力組合，特別是腫瘤、遺傳病、感染病及遺傳藥理學領域。在該等領域，本集團計劃繼續提高診斷檢測技術，更新設備，並在適當情況下招募更多人員以支持擴張。隨著本集團的診斷能力擴大，我們計劃向更多非醫療機構客戶（如公司及政府機構）推廣其服務，以增強其為客戶提供全方位醫學運營服務的能力。透過不斷拓展其能力，本集團亦致力與醫院合作，為患者提供精準醫療解決方案。

本集團相信，由於越來越多的患者尋求定制化醫療解決方案，精準醫療將於醫療行業中呈增長趨勢。診斷檢測對增強精準醫療至關重要，因為精確的診斷檢測可讓醫生瞭解患者的病症，從而定制其治療方案。憑藉其於診斷檢測領域的經驗及市場領導地位，本集團擬率先採取行動以抓住這一行業機遇。

#### *繼續吸引及培訓我們的人才*

本集團計劃繼續吸引及培訓天資卓越且經驗豐富的人員，以支持不斷擴展業務。特別是，本集團計劃關注於技術及醫療人員以及管理層人員，本集團認為這些人員是業務的中流砥柱。本集團擬建立具有等級結構及相應薪酬計劃的員工晉升及發展系統。本集團亦可能擬定激勵計劃，以於未來激勵及協調員工的利益。本集團亦將為不同部門實施培訓計劃，以增強其專業及技術知識。本集團亦計劃對雲康醫學與健康管理學院增加投資，以吸引及培養更多人才。

## FINANCIAL REVIEW

### Overview

The financial summary set out below is extracted or calculated from the unaudited financial statements of the Group for the Reporting Period which were prepared in accordance with the applicable disclosure provisions of the Listing Rules, including compliance with Hong Kong Accounting Standard 34 Interim Financial Reporting, issued by the Hong Kong Institute of Certified Public Accountants.

### Revenue

Revenue of the Group amounted to RMB1,378.7 million for Reporting Period, representing an increase of 81.9% compared to RMB758.0 million for the six months ended June 30, 2021. Such increase was primarily attributable to the rapid growth of the Group's diagnostic testing services during the Reporting Period which was driven by the promotion of health care policy in mainland China and our professional medical diagnostic capabilities, outstanding capabilities of standardization and innovative business models.

The Group's revenue for the periods indicated is generated from three sectors as demonstrated below:

		For six months ended June 30, 截至六月三十日止六個月		
		2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	Change 變動
Diagnostic outsourcing services	診斷外包服務	680,362	483,209	40.8%
Diagnostic testing services for medical institution alliances	為醫聯體提供的診斷檢測服務	650,700	244,449	166.2%
Diagnostic testing services for non-medical institutions	為非醫療機構提供的診斷檢測服務	47,594	30,372	56.7%
		<b>1,378,656</b>	758,030	81.9%

## 財務回顧

### 概覽

以下財務摘要乃根據本集團於報告期內的未經審核財務報表摘取或計算，該財務報表乃根據上市規則之適用披露條文編製，包括遵守香港會計師公會頒佈之香港會計準則第34號中期財務報告。

### 收益

報告期內，本集團的收益為人民幣1,378.7百萬元，較截至2021年6月30日止六個月的人民幣758.0百萬元增加81.9%。該增加由於在中國內地醫療政策的促進及推動下，基於本集團專業的醫療診斷能力、強大的標準化能力及創新業務模式帶動下，本集團的診斷檢測服務於報告期內呈現快速增長所致。

本集團於所示期間的收益來源於下列三個分部：

## Management Discussion and Analysis 管理層討論及分析

### *Diagnostic Outsourcing Services*

Revenue generated from diagnostic outsourcing services increased by 40.8% from RMB483.2 million for the six months ended June 30, 2021 to RMB680.4 million for the six months ended June 30, 2022, primarily due to the performance of key products of the Group maintained robust growth during the Reporting Period; in particular, business in key disease areas such as tumor, infectious diseases and blood diseases were on high-quality development trajectory, driving further growth in revenue from the diagnostic outsourcing services.

### *Diagnostic Testing Services for Medical Institution Alliances*

Revenue generated from diagnostic testing services for medical institution alliances increased by 166.2% from RMB244.4 million for the six months ended June 30, 2021 to RMB650.7 million for the six months ended June 30, 2022. The increase was primarily due to (i) the increased number of on-site diagnostic centers from 275 as of December 31, 2021 to 350 as of June 30, 2022; and (ii) the further improved services capability and expanded service scope of the on-site diagnostic centers after the preliminary construction and operation, resulting in a rapid growth of the average revenue of the unit on-site diagnostic centers. As of June 30, 2022, the semi-annual average revenue of the on-site diagnostic centers was RMB1.9 million (a full-year average revenue of RMB2.2 million in 2021). As a crucial business of the Group, diagnostic testing services for medical institution alliances are constituting an increasing proportion of the Group's total revenue which increased from 32.2% for the six months ended June 30, 2021 to 47.2% for the six months ended June 30, 2022.

### *診斷外包服務*

診斷外包服務所得收益由截至2021年6月30日止六個月的人民幣483.2百萬元增加40.8%至截至2022年6月30日止六個月的人民幣680.4百萬元，主要由於報告期內，本集團重點產品業績保持穩健增長，其中腫瘤、感染性疾病、血液疾病等重點疾病領域業務均呈現高質量發展趨勢，推動診斷外包服務收入規模進一步擴大。

### *為醫聯體提供的診斷檢測服務*

為醫聯體提供的診斷檢測服務所得收益由截至2021年6月30日止六個月的人民幣244.4百萬元增加166.2%至截至2022年6月30日止六個月的人民幣650.7百萬元。該增加主要由於(i)現場診斷中心數量從截至2021年12月31日的275間增長到截至2022年6月30日的350間；及(ii)現場診斷中心經過初期的建設和運營，其服務水準及服務範圍進一步擴大，單位現場診斷中心的平均收益增長迅速。截至2022年6月30日，現場診斷中心的半年度平均收益為人民幣1.9百萬元(2021全年的平均收益為人民幣2.2百萬元)。作為本集團的重要業務，醫聯體診斷檢測服務佔本集團的總收益百分比不斷增加，由截至2021年6月30日止六個月的32.2%增加至截至2022年6月30日止六個月的47.2%。



#### *Diagnostic Testing Services for Non-Medical Institutions*

Diagnostic testing services for non-medical institutions are mainly provided through our outpatient clinics, serving individual customers who are general public and employees of our non-medical institution customers. During the Reporting Period, revenue generated from diagnostic testing services for non-medical institutions increased by 56.7% from RMB30.4 million for the six months ended June 30, 2021 to RMB47.6 million for the six months ended June 30, 2022, primarily due to the significant increase in demand for COVID-19 tests by individual customers and non-medical institution customers under the ongoing impact of COVID-19 epidemic.

#### **Cost of Revenue**

The Group's cost of revenue consists of (i) cost of reagent and pharmaceuticals consumed; (ii) staff costs; (iii) depreciation expenses, which primarily include depreciation of property, plant and equipment and right-of-use assets; (iv) subcontracting charges, which primarily include outsourcing service fees paid; and (v) other costs, which are directly attributable to the generation of revenue.

The Group's cost of revenue increased by 95.6% from RMB372.0 million for the six months ended June 30, 2021 to RMB727.6 million for the six months ended June 30, 2022, which are line with the increase in revenue.

#### **Gross Profit and Gross Profit Margin**

As of result of the aforementioned factors, the Group's gross profit increased by 68.6% from RMB386.1 million for the six months ended June 30, 2021 to RMB651.1 million for the six months ended June 30, 2022. The Group's overall gross profit margin slightly decreased from 50.9% for the six months ended June 30, 2021 to 47.2% for the six months ended June 30, 2022, primarily due to the decrease of average unit price of COVID-19 tests during the Reporting Period under the continuing impact of COVID-19 and relevant government pricing policies.

#### *為非醫療機構提供的診斷檢測服務*

為非醫療機構提供的診斷檢測服務主要通過門診診所提供，服務於普通公眾的個人客戶以及我們的非醫療機構客戶的員工。於報告期間，為非醫療機構提供的診斷檢測服務所得收益由截至2021年6月30日止六個月的人民幣30.4百萬元增加56.7%至截至2022年6月30日止六個月的人民幣47.6百萬元，主要由於個人客戶及非醫療機構客戶在COVID-19疫情持續影響下對COVID-19檢測的需求大幅增加所致。

#### **收益成本**

本集團的收益成本主要包括(i)所耗用試劑及藥品成本；(ii)員工成本；(iii)折舊支出，主要包括物業、廠房及設備以及使用權資產折舊；(iv)分包費用，主要包括支付的外包服務費用；及(v)其他成本，直接歸因於產生收益。

本集團的收益成本由截至2021年6月30日止六個月的人民幣372.0百萬元增加95.6%至截至2022年6月30日止六個月的人民幣727.6百萬元，此乃與收益增加一致。

#### **毛利及毛利率**

由於上述因素，本集團的毛利由截至2021年6月30日止六個月的人民幣386.1百萬元增加68.6%至截至2022年6月30日止六個月的人民幣651.1百萬元。本集團的整體毛利率由截至2021年6月30日止六個月的50.9%略降至截至2022年6月30日止六個月的47.2%，主要由於在COVID-19疫情持續影響下報告期間COVID-19檢測的平均單價減少及相關政府定價政策所致。

## Management Discussion and Analysis

### 管理層討論及分析

#### Other Income and Gains, Net

The Group's net amount of other income and gains increased by 101.3% to RMB4.9 million for six months ended June 30, 2022, as compared to RMB2.4 million for six months ended June 30, 2021. The increase was primarily attributable to government grants and subsidies received or to be received.

The government grants include those grants from the local government in recognition of the entitlement of high and new technology enterprises, and the medical institutions' contribution to local economy's development. There are no unfulfilled conditions or other contingencies attached to these grants.

#### Selling Expenses

The Group's selling expenses increased by 81.1% from RMB121.0 million for the six months ended June 30, 2021 to RMB219.1 million for the six months ended June 30, 2022, primarily due to the increase of the Group's revenue during the Reporting Period. The proportion of selling expenses in the total revenue was relatively stable, which was 16.0% and 15.9% for the six months ended June 30, 2021 and the six months ended June 30, 2022, respectively.

#### Administrative Expenses

The Group's administrative expenses increased by 80.7% from RMB71.2 million for the six months ended June 30, 2021 to RMB128.6 million for the six months ended June 30, 2022, primarily due to expenses on the recruitment of talents to support the Group's expanding business and R&D, as well as the listing expenses incurred in connection with our preparation for the Company's global offering. The Group's administrative expenses for the six months ended June 30, 2021 accounted for 9.4% of the total revenue, while the ratio was 9.3% for the six months ended June 30, 2022, which remains stable.

The Group's R&D expenses increased by 62.2% from RMB15.6 million for six months ended June 30, 2021 to RMB25.4 million for six months ended June 30, 2022, mainly due to the increased investments in on-going and newly kick-off R&D projects.

#### 其他收入及收益淨額

本集團的其他收入及收益淨額由截至2021年6月30日止六個月的人民幣2.4百萬元增加101.3%至截至2022年6月30日止六個月的人民幣4.9百萬元。該增加主要歸因於已收或將收政府補助及補貼。

政府補助包括地方政府為確認高新技術企業的資格，及醫療機構對當地經濟發展的貢獻而發放的補助。該等補助並無附帶未達成條件或其他或然事項。

#### 銷售開支

本集團的銷售開支由截至2021年6月30日止六個月的人民幣121.0百萬元增加81.1%至截至2022年6月30日止六個月的人民幣219.1百萬元，主要由於報告期內本集團收益增加。銷售開支佔整體收益的比例相對穩定，於截至2021年6月30日止六個月及截至2022年6月30日止六個月分別為16.0%及15.9%。

#### 行政開支

本集團的行政開支由截至2021年6月30日止六個月的人民幣71.2百萬元增加80.7%至截至2022年6月30日止六個月的人民幣128.6百萬元，主要由於招攬人才以支持本集團擴展業務及研發開支，以及籌備本公司全球發售而產生的上市開支。本集團截至2021年6月30日止六個月的行政開支佔總收益9.4%，而截至2022年6月30日止六個月的這一比率為9.3%，保持在穩定水平。

本集團的研發開支由截至2021年6月30日止六個月的人民幣15.6百萬元增加62.2%至截至2022年6月30日止六個月的人民幣25.4百萬元，主要由於對持續進行及新開展的研發項目的投資增加所致。

### Impairment Losses on Financial Assets

The Group's impairment losses on financial assets were mainly provisions for accounts receivable. For the six months ended June 30, 2022, the Group's impairment losses on financial assets were approximately RMB20.9 million, representing an increase of 110.4% year-on-year, mainly due to the increase in the Group's trade receivables with the growth of business scale.

### Finance Costs

The Group's net amount of finance costs decreased from RMB4.9 million for the six months ended June 30, 2021 to RMB3.8 million for the six months ended June 30, 2022, primarily due to the decrease in interest expense on interest-bearing borrowings.

### Profit before Tax

As of result of the aforementioned factors, the Group recorded profit before tax of RMB283.5 million for the six months ended June 30, 2022, compared to RMB181.5 million for the six months ended June 30, 2021. This was mainly attributable to the significant increase in revenue generated from the Company's diagnostic testing services for medical institutional alliances, which had a positive impact on the profitability of the Company.

### Income Tax Expenses

The Group's income tax expenses increased from RMB33.5 million for the six months ended June 30, 2021 to RMB48.7 million for the six months ended June 30, 2022, primarily due to the increase in the Group's taxable income.

### 金融資產減值虧損

本集團金融資產減值虧損主要為就應收款項作出的撥備。截至2022年6月30日止六個月，本集團金融資產減值虧損約為人民幣20.9百萬元，同比去年增長110.4%，主要由於本集團貿易應收款項隨著業務規模增長而增加所致。

### 財務成本

本集團的財務成本淨額由截至2021年6月30日止六個月的人民幣4.9百萬元減少至截至2022年6月30日止六個月的人民幣3.8百萬元，主要由於計息借款的利息開支減少所致。

### 除稅前溢利

由於上述因素，本集團於截至2022年6月30日止六個月錄得除稅前溢利人民幣283.5百萬元，而截至2021年6月30日止六個月錄得除稅前溢利人民幣181.5百萬元。此乃主要由於本公司為醫聯體提供的診斷檢測服務產生的收益大幅增長，給本公司盈利能力帶來正面影響。

### 所得稅開支

本集團的所得稅開支由截至2021年6月30日止六個月的人民幣33.5百萬元增加至截至2022年6月30日止六個月的人民幣48.7百萬元，主要由於本集團的應課稅收入增加所致。



## Management Discussion and Analysis

### 管理層討論及分析

#### Property and Equipment

The Group's property and equipment consist of property and buildings, medical equipment, vehicles, furniture and office equipment, leasehold improvements, construction in progress, and right-of-use assets.

The Group's property and equipment increased from RMB485.2 million as at June 30, 2021 to RMB641.9 million as at June 30, 2022, primarily due to the Group's investment in medical equipment and new leases entered into for setting up laboratories.

#### Financial Assets Measured at Fair Value

The Group's financial assets measured at fair value comprise financial assets designated at FVOCI and financial assets designated at FVTPL, all of which are level 3 instruments based on the fair value hierarchy.

We use valuation techniques to determine the fair value of our level 3 instruments. External valuation experts will be involved when necessary. During the six months ended June 30, 2022, the fair value changes on financial assets measured at FVOCI and FVTPL are considered as immaterial.

#### Inventories

The Group's inventories primarily consist of reagents and pharmaceuticals.

The Group's inventories increased from RMB41.7 million as at December 31, 2021 to RMB74.2 million as at June 30, 2022, which is in line with the Group's business growth.

#### 物業及設備

本集團的物業及設備包括物業及樓宇、醫療設備、汽車、傢具及辦公設備、租賃物業裝修、在建工程及使用權資產。

本集團的物業及設備由2021年6月30日的人民幣485.2百萬元增加至2022年6月30日的人民幣641.9百萬元，主要由於本集團投資醫療設備及就設立實驗室簽訂新租約。

#### 按公平值計量的金融資產

本集團按公平值計量的金融資產包括指定按公平值計入其他全面收益的金融資產及指定按公平值計入損益的金融資產，均為公平值層級的第3級工具。

我們使用估值技術釐定第3級工具的公平值。於必要時，外部估值專家將會參與。截至2022年6月30日止六個月，按公平值計入其他全面收益及按公平值計入損益計量的金融資產公平值變動被視為不重大。

#### 存貨

本集團的存貨主要包括試劑及藥品。

本集團的存貨由2021年12月31日的人民幣41.7百萬元增加至2022年6月30日的人民幣74.2百萬元，與本集團的業務增長一致。

### Trade and Other Receivables and Prepayments

The Group's trade and other receivables and prepayments increased from RMB886.9 million as at December 31, 2021 to RMB1,565.6 million as at June 30, 2022, primarily due to increased orders of services received during the period. The Group's credit period with customers is generally within 180 days. Some of the Group's trade receivables age over 180 days as some of the Group's key customers are public hospitals and Chinese Center for Disease Control and Prevention (中國疾病預防控制中心), who generally have the settlement with which is usually time-consuming and involves prolonged internal administrative procedures.

### Trade and Other Payables

The Group's trade and other payables increased from RMB556.7 million as at December 31, 2021 to RMB855.2 million as at June 30, 2022, primarily due to procurement of equipment and reagent in connection to the increasing revenue and accrued expenses during daily operations.

### Capital Management

The Group's objectives in respect of managing capital are to safeguard its ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

### Liquidity and Financial Resources

The Group's cash and cash equivalents increased from RMB800.7 million as at December 31, 2021 to RMB1,083.5 million as at June 30, 2022, primarily attributable to the cash and cash equivalents received in the global offering on the Listing Date.

### 貿易及其他應收款項以及預付款項

本集團的貿易及其他應收款項及預付款項由2021年12月31日的人民幣886.9百萬元增加至2022年6月30日的人民幣1,565.6百萬元，主要由於期內獲得的服務訂單增加。本集團向客戶提供的信貸期通常為180天。本集團部分貿易應收款項的賬齡超過180天，由於本集團若干主要客戶為公立醫院及中國疾病預防控制中心，而該等客戶結算通常耗時較久，並涉及漫長的內部行政程序。

### 貿易及其他應付款項

本集團的貿易及其他應付款項由2021年12月31日的人民幣556.7百萬元增加至2022年6月30日的人民幣855.2百萬元，主要由於與日常營運期間收益及應計開支增加有關的設備及試劑採購。

### 資本管理

本集團的資本管理目標是保障其持續經營的能力，以為股東提供回報及為其他利益關係者提供利益，同時維持最佳的資本結構以減少資本成本。

### 流動資金及財務資源

本集團的現金及現金等價物由2021年12月31日的人民幣800.7百萬元增加至2022年6月30日的人民幣1,083.5百萬元，主要由於上市日期全球發售獲得現金及現金等價物。

## Management Discussion and Analysis

### 管理層討論及分析

#### Net Current Assets

The Group had net current assets increased from RMB872.4 million as at December 31, 2021 to RMB1,674.6 million as at June 30, 2022.

#### Key Financial Ratios

The following table set forth the Group's key financial ratios as at the dates or for the periods indicated.

#### 流動資產淨值

本集團的流動資產淨值由2021年12月31日的人民幣872.4百萬元增加至2022年6月30日的人民幣1,674.6百萬元。

#### 主要財務比率

下表載列本集團於所示日期或期間的主要財務比率。

		For the six months ended June 30, 截至六月三十日止六個月	
		2022 二零二二年	2021 二零二一年
Gross profit margin <sup>(1)</sup>	毛利率 <sup>(1)</sup>	47.2%	50.9%
		As at June 30, 2022 於二零二二年 六月三十日	As at December 31, 2021 於二零二一年 十二月三十一日
Current ratio <sup>(2)</sup>	流動比率 <sup>(2)</sup>	2.41	2.00
Quick ratio <sup>(3)</sup>	速動比率 <sup>(3)</sup>	2.35	1.95
Debt to asset ratio <sup>(4)</sup>	資產負債比率 <sup>(4)</sup>	0.37	0.41

#### Notes:

- (1) Gross profit margin is calculated based on gross profit divided by revenue and multiplied by 100%.
- (2) Current ratio is calculated based on total current assets divided by total current liabilities.
- (3) Quick ratio is calculated based on total current assets less inventories divided by total current liabilities.
- (4) Debt to asset ratio is calculated as total liabilities divided by total assets.

#### 附註：

- (1) 毛利率乃按毛利除以收益再乘以100%計算。
- (2) 流動比率乃按流動資產總值除以流動負債總值計算。
- (3) 速動比率乃按流動資產總值減存貨再除以流動負債總值計算。
- (4) 資產負債比率乃按負債總值除以資產總值計算。



### Contingent Liabilities

As at June 30, 2022, the Group did not have any material contingent liabilities, guarantee or any litigation or claim of material importance, pending or threatened against any of its member.

### Foreign Exchange Risk

The Group mainly operates in China. Except for bank deposits denominated in Hong Kong Dollars, the Group does not have any other material direct exposure to foreign exchange fluctuations. The management will continue to monitor foreign exchange risk, take prudent measures and develop hedging strategy as appropriate to reduce foreign exchange risks.

### Cash Flow and Fair Value Interest Rate Risk

The Group's interest-rate risk arises from borrowings. Borrowings issued at variable rates expose the Group to cash flow interest-rate risk. Borrowings issued at fixed rates expose the Group to fair value interest-rate risk. The Group currently has not used any interest rate swap arrangements but will consider hedging interest rate risk should the need arise.

Other than interest-bearing short-term deposits, the Group has no other significant interest-bearing assets. The Board does not anticipate that there is any significant impact to interest-bearing assets resulted from the changes in interest rates because the interest rates of short-term deposits are not expected to change significantly.

### Credit Risk

The Group is exposed to credit risk in relation to its trade and other receivables, amounts due from related parties and cash deposits at banks. The carrying amount of each class of the above financial assets represents the Group's maximum exposure to credit risk in relation to the corresponding class of financial assets.

### Liquidity Risk

To manage the liquidity risk, the Group's policy is to regularly monitor its liquidity requirements and compliance with lending covenants, to ensure that it maintains sufficient reserve of cash and adequate committed lines of funding from major financial institutions to meet its liquidity requirements in the short and long term.

### 或然負債

於2022年6月30日，本集團並無任何重大或然負債、擔保或其任何成員公司未決或面臨的任何重大訴訟或申索。

### 外匯風險

本集團業務主要集中於中國。除以港幣計值的銀行存款外，本集團並未面對任何其他重大直接匯率波動風險。管理層將繼續監察外匯風險，並採取審慎措施，適時制定對沖策略以減低匯兌風險。

### 現金流量及公平值利率風險

本集團的利率風險來自借款。按浮動利率計息的借款使本集團面臨現金流量利率風險。按固定利率計息的借款使本集團面臨公平值利率風險。本集團目前並無採用任何利率掉期安排，但會在有需要時考慮對沖利率風險。

除計息短期存款外，本集團並無其他重大計息資產。由於預期短期存款的利率不會有重大變動，故董事會預期利率變動不會對計息資產造成任何重大影響。

### 信貸風險

本集團面臨與貿易及其他應收款項、應收關聯方款項及銀行現金存款有關的信貸風險。上述各類金融資產的賬面值代表本集團就相應金融資產類別面臨的最高信貸風險。

### 流動資金風險

為管理流動資金風險，本集團的政策為定期監察其流動資金需求及遵守借貸契諾的情況，以確保具有充裕現金儲備及獲主要金融機構承諾提供足夠資金額度，以應付短期及長期流動資金需求。

## Management Discussion and Analysis

### 管理層討論及分析

#### Borrowings and Gearing Ratio

The Group had borrowings, including interest-bearing borrowings, of RMB442.1 million as at June 30, 2022.

As at June 30, 2022, the gearing ratio of the Group (calculated as total interest-bearing borrowings and lease liabilities divided by total equity as of the same date) decreased to 20.9%, compared to 25.0% as of December 31, 2021.

#### Charge on Asset

As at June 30, 2022, there was no charge on assets of the Group.

#### Significant Investments, Material Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures during the Reporting Period

The Group did not make any material investments, material acquisitions or disposals of subsidiaries, associates and joint ventures during the Reporting Period.

#### Events after the Reporting Period

No important events affecting the Group occurred since June 30, 2022 and up to the date of this report.

#### Future Plans for Material Investments and Capital Assets

Except the commitments disclosed in the Note 22 to the interim condensed consolidated financial statements, the Group does not have any concrete committed plans for material investments and capital assets in 2022.

#### Employees and Remuneration

As at June 30, 2022, the Group had 2,476 employees (as at June 30, 2021: 1,574). The total remuneration cost incurred by the Group for the six months ended June 30, 2022 was RMB200.9 million (for the six months ended June 30, 2021: RMB113.2 million). The remuneration package of the Group's employees includes salary and bonus, which are generally determined by their qualifications, industry experience, position and performance. The Group makes contributions to social insurance and housing provident funds as required by the PRC laws and regulations.

#### 借款及資產負債比率

於2022年6月30日，本集團的借款（包括計息借款）為人民幣442.1百萬元。

於2022年6月30日，本集團的資本負債比率（按計息借款及租賃負債總值除以截至同日的總權益計算）降至20.9%，而截至2021年12月31日為25.0%。

#### 資產押記

於2022年6月30日，本集團概無資產押記。

#### 於報告期內的重重大投資、重大收購及出售附屬公司、聯營公司及合營企業

本集團於報告期內並無進行任何重大投資、重大收購或出售附屬公司、聯營公司及合營企業。

#### 報告期後事項

自2022年6月30日起直至本報告日期並無發生影響本集團的重要事項。

#### 有關重大投資及資本資產的未來計劃

除中期簡明綜合財務報表附註22所披露的承諾外，本集團於2022年並無任何有關重大投資及資本資產的具體承諾計劃。

#### 僱員及薪酬

於2022年6月30日，本集團有2,476名僱員（於2021年6月30日：1,574名）。截至2022年6月30日止六個月，本集團產生的總薪酬成本為人民幣200.9百萬元（截至2021年6月30日止六個月：人民幣113.2百萬元）。本集團僱員的薪酬組合包括薪金及花紅，一般按資歷、行業經驗、職位及表現釐定。本集團根據中國法律法規的規定繳納社會保險及住房公積金。

## Corporate Governance and Other Information 企業管治及其他資料

### DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at June 30, 2022, the interests and short positions of the Directors and chief executives of the Company in the Shares, underlying Shares or debentures of the Company or any of the associated corporations of the Company (within the meaning of Part XV of the SFO), which were required (a) to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO); or (b) pursuant to section 352 of the SFO, to be entered in the register referred to therein; or (c) to be notified to the Company and the Stock Exchange pursuant to the Model Code, were as follows:

### 董事及最高行政人員於股份、相關股份及債權證中的權益及淡倉

於2022年6月30日，本公司董事及最高行政人員於本公司或本公司的任何相聯法團（定義見證券及期貨條例第XV部）的股份、相關股份或債權證中所擁有(a)根據證券及期貨條例第XV部第7及第8分部須知會本公司及聯交所的權益及淡倉（包括根據證券及期貨條例的有關條文被當作或視作擁有的權益及淡倉）；或(b)根據證券及期貨條例第352條須登記於該條所指登記冊的權益及淡倉；或(c)根據標準守則須知會本公司及聯交所的權益及淡倉載列如下：

Name of Director	Capacity/nature of interest	Number of Ordinary Shares	Approximate percentage of shareholding in the total issued share capital (%) 佔已發行總股本的概約股權百分比(%)
董事姓名	身份／權益性質	普通股數目	
Mr. Zhang Yong 張勇先生	Interested in a controlled corporation 於受控制法團的權益	250,108,000 <sup>(1)</sup> (L)	40.25% (L)

(L) denotes a long position

(L) 指好倉

#### Notes:

#### 附註：

(1) These shares are directly held by YK Development, which is held as to 64.04% and controlled by Huizekx Limited, which is wholly-owned by Mr. Zhang Yong. Therefore, Huizekx Limited and Mr. Zhang Yong are deemed to be interested in the Shares held by YK Development under the SFO.

(1) 該等股份由YK Development直接持有，YK Development由Huizekx Limited持有及控制64.04%的權益，而Huizekx Limited由張勇先生全資擁有。因此，根據證券及期貨條例，Huizekx Limited及張勇先生被視為於YK Development所持股份中擁有權益。



## Corporate Governance and Other Information 企業管治及其他資料

Save as disclosed above, as at June 30, 2022, none of the Directors or chief executives of the Company has or is deemed to have any interests or short positions in the Shares, underlying Shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which will be required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO); or which will be required to be recorded in the register to be kept by the Company pursuant to Section 352 of the SFO, or which will be required, pursuant to the Model Code, to be notified to the Company and the Stock Exchange.

### SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at June 30, 2022, the followings are the persons, other than the Directors or chief executives of the Company, who had interests or short positions in the Shares and underlying Shares which would be required to be notified to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO; or as recorded in the register of interests required to be kept by the Company pursuant to Section 336 of Part XV of the SFO:

除上文所披露者外，於2022年6月30日，概無董事或本公司最高行政人員於本公司或其任何相聯法團（定義見證券及期貨條例第XV部）的股份、相關股份中或債權證中擁有或被視作擁有須根據證券及期貨條例第XV部第7及8分部條文知會本公司及聯交所的任何權益或淡倉（包括根據證券及期貨條例的有關條文被當作或視作擁有的權益及淡倉）；或須登記於本公司根據證券及期貨條例第352條所指登記冊的權益及淡倉；或根據標準守則須知會本公司及聯交所的權益及淡倉。

### 主要股東於股份及相關股份中的權益及淡倉

於2022年6月30日，下列人士（非董事或本公司的最高行政人員）於股份及相關股份中擁有根據證券及期貨條例第XV部第2及3分部條文須知會本公司及聯交所的權益或淡倉；或登記於本公司根據證券及期貨條例第XV部第336條所存置登記冊的權益及淡倉：

## Corporate Governance and Other Information 企業管治及其他資料

Name of substantial Shareholder	Capacity/nature of interest	Number of Ordinary Shares	Approximate percentage of shareholding in the total issued share capital (%) 佔已發行總股本的概約股權百分比(%)
主要股東姓名／名稱	身份／權益性質	普通股數目	
Zhang Yong 張勇	Interested in a controlled corporation 於受控制法團的權益	250,108,000 (L)	40.25% (L)
Huizekx Limited <sup>(1)</sup>	Interested in a controlled corporation 於受控制法團的權益	250,108,000 (L)	40.25% (L)
Mouduans Limited <sup>(2)</sup>	Interested in a controlled corporation 於受控制法團的權益	250,108,000 (L)	40.25% (L)
Tongfuzc Limited <sup>(2)</sup>	Interested in a controlled corporation 於受控制法團的權益	250,108,000 (L)	40.25% (L)
WJJR Investment Limited <sup>(2)</sup>	Interested in a controlled corporation 於受控制法團的權益	250,108,000 (L)	40.25% (L)
Jin Jun Ying Limited <sup>(2)</sup>	Interested in a controlled corporation 於受控制法團的權益	250,108,000 (L)	40.25% (L)
Source Capital RW Limited <sup>(2)</sup>	Interested in a controlled corporation 於受控制法團的權益	250,108,000 (L)	40.25% (L)
YK Development <sup>(1)</sup>	Beneficial owner 實益擁有人	250,108,000 (L)	40.25% (L)
Da An Gene <sup>(3)</sup> 達安基因 <sup>(3)</sup>	Interested in a controlled corporation 於受控制法團的權益	209,783,000 (L)	33.76% (L)
Guangzhou Daan Gene <sup>(3)</sup> 廣州市達安基因 <sup>(3)</sup>	Interested in a controlled corporation 於受控制法團的權益	209,783,000 (L)	33.76% (L)
Daan International <sup>(3)</sup> 達安國際 <sup>(3)</sup>	Beneficial owner 實益擁有人	209,783,000 (L)	33.76% (L)

(L) denotes a long position (L) 指好倉

## Corporate Governance and Other Information

### 企業管治及其他資料

#### Notes:

- (1) YK Development is held as to 64.04% and controlled by Huizekx Limited, which is wholly-owned by Mr. Zhang Yong. Therefore, Huizekx Limited is deemed to be interested in the shares of the Company held by YK Development under the SFO.
- (2) YK Development is held as to approximately 23.47%, 6.95%, 3.04%, 0.50% and 2.00%, by Mouduans Limited, Tongfuzc Limited, WJJR Investment Limited, Jin Jun Ying Limited and Source Capital RW Limited, respectively. Pursuant to Guidance Letter HKEX GL89-16, Huizekx Limited, Mouduans Limited, Tongfuzc Limited, WJJR Investment Limited, Jin Jun Ying Limited, Source Capital RW Limited and YK Development are a group of Controlling Shareholders of the Company.
- (3) Daan International is wholly-owned by Guangzhou Daan Gene, a company wholly-owned by Da An Gene. Therefore, Guangzhou Daan Gene and Da An Gene is deemed to be interested in the Shares held by Daan International under the SFO.

Save as disclosed above, as at June 30, 2022, the Directors and chief executives of the Company are not aware of any other person (other than the Directors or chief executives of the Company) who had an interest or short position in the Shares or underlying Shares of the Company which would be required to be notified to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO; or as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO.

#### 附註：

- (1) YK Development由張勇先生全資擁有的Huizekx Limited持有及控制64.04%權益。因此，根據證券及期貨條例，Huizekx Limited被視為於YK Development所持本公司股份中擁有權益。
- (2) YK Development由Mouduans Limited、Tongfuzc Limited、WJJR Investment Limited、Jin Jun Ying Limited及Source Capital RW Limited分別持有約23.47%、6.95%、3.04%、0.50%及2.00%的權益。根據指引信HKEX GL89-16，Huizekx Limited、Mouduans Limited、Tongfuzc Limited、WJJR Investment Limited、Jin Jun Ying Limited、Source Capital RW Limited及YK Development為本公司的一組控股股東。
- (3) 達安國際由廣州市達安基因全資擁有，而廣州市達安基因是一家由達安基因全資擁有的公司。因此，根據證券及期貨條例，廣州市達安基因及達安基因被視為於達安國際所持股份中擁有權益。

除上文所披露者外，於2022年6月30日，董事及本公司最高行政人員概不知悉任何其他人士（本公司的董事或最高行政人員除外）於本公司的股份或相關股份中擁有根據證券及期貨條例第XV部第2及3分部條文須知會本公司及聯交所的任何權益或淡倉；或登記於本公司根據證券及期貨條例第336條所存置之登記冊內的權益及淡倉。



## Corporate Governance and Other Information 企業管治及其他資料

### DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as disclosed in this interim report, at no time from the Listing Date to the date of this interim report was the Company or any of its subsidiaries, a party to any arrangement that would enable the Directors to acquire benefits by means of acquisition of the Shares in, or debentures of, the Company or any other body corporate, and none of the Directors or any of their spouses or children under the age of 18 were granted any right to subscribe for the equity or debt securities of the Company or any other body corporate or had exercised any such right.

### COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company strives to achieve high corporate governance standards. The Board believes that high corporate governance standards are essential in providing a framework for the Group to safeguard the interests of shareholders and to enhance corporate value and accountability.

The Company was listed on the Main Board of the Stock Exchange on the Listing Date. The Company has adopted the principles and code provisions of the Corporate Governance Code as the basis of the Company's corporate governance practices.

### 董事收購股份或債權證的權利

除本中報所披露者外，於上市日期及直至本中報日期期間，本公司或其任何附屬公司均非任何安排的其中一方以讓董事通過收購本公司或任何其他法人團體的股份或債權證的方式收取利益，亦概無董事或任何彼等的配偶或18歲以下的子女獲授任何權利以認購本公司或任何其他法人團體的股本或債務證券或已行使任何該等權利。

### 遵守企業管治守則

本公司致力達致高水平的企業管治。董事會相信高水平的企業管治對本集團建立框架而言屬不可或缺，以保障股東利益以及提升企業價值及問責程度。

本公司於上市日期在聯交所主板上市。本公司已採納企業管治守則的原則及守則條文作為本公司企業管治常規基準。

## Corporate Governance and Other Information 企業管治及其他資料

From the Listing Date and up to the date of this interim report, the Company has complied with all applicable code provisions set out in the Corporate Governance Code except for the deviations from code provision C.2.1 of the Corporate Governance Code. Pursuant to code provision C.2.1 of the Corporate Governance Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. The division of responsibilities between the chairman and chief executive should be clearly established and set out in writing. Mr. Zhang Yong currently serves as the chairman of the Board and the chief executive officer of the Company. He joined the Group on May 28, 2008 and has been operating and managing the Group since then. The Directors believe that it is beneficial to the business operations and management of the Group that Mr. Zhang Yong continues to serve as both the chairman of the Board and the chief executive officer of the Company.

The Company will continue to regularly review and monitor its corporate governance practices to ensure compliance with the Corporate Governance Code, and maintain a high standard of corporate governance practices.

### COMPLIANCE WITH THE MODEL CODE

The Company has adopted the Model Code as its securities code to regulate the dealing by the Directors in securities of the Company. Specific enquiries have been made to all the Directors and the Directors have confirmed that they have complied with the Model Code from the Listing Date and up to the date of this interim report. The Company's relevant employees, who are likely to be in possession of inside information of the Company, have also been subject to the Model Code for securities transactions. No incident of non-compliance of the Model Code by the Company's relevant employees was noted by the Company from the Listing Date and up to the date of this interim report.

The Company has also established a policy on inside information to comply with its obligations under the Securities and Futures Ordinance and the Listing Rules. In case when the Company is aware of any restricted period for dealings in the Company's securities, the Company will notify its Directors and relevant employees in advance.

自上市日期起至本中報日期，本公司已遵守企業管治守則所有適用守則條文，惟偏離企業管治守則第C.2.1條守則條文。根據企業管治守則第C.2.1條守則條文，主席與行政總裁的角色應有區分，不應由一人兼任。主席與行政總裁的職責應明確劃分，並以書面方式列明。張勇先生現任本公司董事會主席兼行政總裁。彼於2008年5月28日加入本集團，此後一直經營管理本集團。董事認為，張勇先生繼續兼任本公司董事會主席及行政總裁有利於本集團的業務經營與管理。

本公司將繼續定期檢討及監督其企業管治常規，以確保遵守企業管治守則，並維持高水平的企業管治常規。

### 遵守標準守則

本公司已採納標準守則作為規範董事進行本公司證券交易的證券交易守則。本公司已向全體董事作出具體查詢，董事確認自上市日期起至本中報日期，彼等已遵守標準守則。可能知悉本公司內幕消息的本公司相關僱員進行證券交易時亦受標準守則規限。自上市日期起至本中報日期，本公司未發現本公司相關僱員違反標準守則的事件。

本公司亦已制定內幕消息政策，以履行其於證券及期貨條例和上市規則項下的義務。倘本公司獲悉本公司證券交易之任何受限制期間，本公司將提前通知董事及相關僱員。

## Corporate Governance and Other Information 企業管治及其他資料

### PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

Neither the Company nor any subsidiaries or Consolidated Affiliate Entities of the Group purchased, redeemed or sold any of the listed securities of the Company or any of its subsidiaries from the Listing Date to June 30, 2022.

### CHANGE OF ADDRESS OF HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

With effect from August 15, 2022, the Hong Kong Branch Share Registrar and Transfer Office of the Company, Tricor Investor Services Limited (the “Branch Share Registrar”), will change its address from Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong to

17/F, Far East Finance Centre  
16 Harcourt Road  
Hong Kong

All telephone and facsimile numbers of the Branch Share Registrar will remain unchanged.

### INTERIM DIVIDEND

On August 11, 2022, the Board declared an interim dividend for the six months ended June 30, 2022 of HK\$0.088 per Share (June 30, 2021: nil), which was paid on September 16, 2022 to the shareholders whose names appear on the register of members of the Company on August 25, 2022.

### 購買、出售或贖回上市證券

自上市日期起至2022年6月30日，本公司、本集團任何附屬公司或綜合聯屬實體概無購買、贖回或出售本公司或其任何附屬公司的任何上市證券。

### 更改香港股份過戶登記分處地址

自2022年8月15日起，本公司的香港股份過戶登記分處卓佳證券登記有限公司（「股份過戶登記分處」）的地址將由香港皇后大道東183號合和中心54樓更改為：

香港  
夏慤道16號  
遠東金融中心17樓

股份過戶登記分處的所有電話及傳真號碼將維持不變。

### 中期股息

於2022年8月11日，董事會宣派截至2022年6月30日止六個月的中期股息每股0.088港元（2021年6月30日：無），該等股息已於2022年9月16日派付予於2022年8月25日名列本公司股東名冊的股東。



## Corporate Governance and Other Information 企業管治及其他資料

### CHANGES IN THE INFORMATION OF THE DIRECTORS

Mr. Zhou Weiqun tendered his resignation as a non-executive Director of the Company with effect from July 11, 2022 and Dr. Wang Ruihua was appointed as a non-executive Director of the Company with effect from the same day. For details, please refer to the Company's announcement dated July 11, 2022.

Mr. Zhou Xinyu tendered his resignation as a non-executive Director of the Company with effect from August 11, 2022 and Ms. Huang Luo was appointed as a non-executive Director of the Company with effect from the same day. For details, please refer to the Company's announcement dated August 11, 2022.

Since the Listing Date, save as disclosed herein, there has been no change in the information of the Directors as required to be disclosed pursuant to Rule 13.51B of the Listing Rules.

### AUDIT COMMITTEE

The Audit Committee consists of one non-executive Director and two independent non-executive Directors, namely Dr. Guo Yunzhao, Mr. Yu Shiyong and Mr. Xie Shaohua (Chairman).

The Audit Committee has reviewed the unaudited consolidated interim financial information for the six months ended June 30, 2022 of the Group. The Audit Committee has also discussed matters with respect to the accounting policies and practices adopted by the Company and internal control measures with senior management members. The Audit Committee does not have any disagreement with the accounting treatment adopted by the Company.

### 董事資料變動

周偉群先生提交辭呈，辭任本公司非執行董事，2022年7月11日起生效。王瑞華博士已獲委任為本公司非執行董事，自同日起生效。有關詳情，請參閱本公司日期為2022年7月11日的公告。

周新宇先生提交辭呈，辭任本公司非執行董事，2022年8月11日起生效。黃珞女士已獲委任為本公司非執行董事，自同日起生效。有關詳情，請參閱本公司日期為2022年8月11日的公告。

自上市日期起，除本報告內所披露者外，董事資料概無任何根據上市規則第13.51B條須予披露的變動。

### 審核委員會

審核委員會包括一名非執行董事及兩名獨立非執行董事，即郭雲釗博士、喻世友先生及謝少華先生（主席）。

審核委員會已審閱本集團截至2022年6月30日止六個月的未經審核綜合中期財務資料。審核委員會亦已與高級管理層成員討論有關本公司採納的會計政策及慣例以及內部控制措施的事宜。審核委員會對本公司採納的會計處理方式無任何異議。

## Corporate Governance and Other Information 企業管治及其他資料

### USE OF PROCEEDS FROM THE GLOBAL OFFERING

The net proceeds from the global offering amounted to approximately HK\$811.8 million. As of June 30, 2022, approximately HK\$93.22 million of the net proceeds of the global offering had been utilized as follows:

### 全球發售所得款項用途

全球發售所得款項淨額約為811.8百萬港元。於2022年6月30日，所得款項淨額中約93.22百萬港元已按下列方式動用：

	Allocation of net proceeds from the global offering in the proportion disclosed in the Prospectus		Proceeds from the global offering utilized as of June 30, 2022	Amounts not yet utilized as of June 30, 2022	Expected timeline of full utilization of the unutilized proceeds from the initial public offering
	招股章程內披露的全球發售所得款項淨額分配比例		於二零二二年六月三十日已動用全球發售所得款項	於二零二二年六月三十日未動用金額	
	HK\$ million 百萬港元	Percentage 比例	HK\$ million 百萬港元	HK\$ million 百萬港元	悉數動用未動用首次公開發售所得款項的預期時間表
Expanding and deepening our medical institution alliance network 擴展及深化我們的醫聯體網絡	446.5	55.0%	29.4	417.1	By the end of 2025 2025年底前
Upgrading and enhancing our operational capabilities of a medical operation service provider 升級及提高我們作為醫學運營服務提供商的的營運能力	162.3	20.0%	19.7	142.6	By the end of 2024 2024年底前
Expanding our diagnostic capabilities and enriching our diagnostic testing portfolio 擴大我們的診斷能力的豐富我們的診斷測試組合	81.2	10.0%	3.0	78.2	By the end of 2024 2024年底前
Potential investment and acquisition opportunities 潛在投資及收購機遇	40.6	5.0%	-	40.6	By the end of 2025 2025年底前
Recruiting and training up our talent pool 招聘及培訓人才庫	40.6	5.0%	0.5	40.1	By the end of 2025 2025年底前
Our working capital and general corporate purposes 我們的營運資金及一般企業目的	40.6	5.0%	40.6	-	N/A 不適用
Total 總計	811.8	100.0%	93.2	718.6	

## Corporate Governance and Other Information 企業管治及其他資料

The unutilized amount is expected to be used in accordance with the Company's plan as disclosed in the Prospectus and stated above. The Company will continue to evaluate market conditions and adopt a prudent and flexible approach for utilizing the net proceeds and will ensure the net proceeds will be used effectively and efficiently for the long-term benefit and development of the Group. The expected timeline of full utilization set out above is based on the Directors' best estimation barring unforeseen circumstances, and is subject to change in light of future development of market conditions.

### EVENT AFTER THE END OF THE REPORTING PERIOD

There has been no material event after the end of the Reporting Period and up to the date of this interim report which requires disclosure in this report.

By Order of the Board  
**Yunkang Group Limited**  
**Zhang Yong**  
*Chairman*

Guangzhou, the PRC, August 11, 2022

未動用款項預期將根據本公司於招股章程內披露及上文所述的計劃予以動用。本公司將繼續評估市場狀況及採納審慎靈活的方針以動用所得款項淨額，並確保所得款項淨額將有效及高效的用於本集團的長期利益和發展。上文所載悉數動用的預期時間表乃基於董事排除不可預見情形的最佳估計，或會因市場狀況的未來發展而發生變動。

### 報告期末後事項

報告期末後直至本中報日期概無須於本報告內披露的重大事項。

承董事會命  
云康集團有限公司  
張勇  
主席

中國廣州，2022年8月11日



## Interim Condensed Consolidated Statement of Comprehensive Income 中期簡明綜合全面收益表

For six months ended June 30,  
截至六月三十日止六個月

		Notes 附註	2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
<b>Continuing operations</b>				
Revenue	持續經營業務 收益	5	1,378,656	758,030
Cost of revenue	收益成本	8	(727,584)	(371,974)
<b>Gross profit</b>			<b>651,072</b>	386,056
Selling expenses	毛利 銷售開支	8	(219,076)	(120,992)
Administrative expenses	行政開支	8	(128,630)	(71,189)
Net impairment losses on financial assets	金融資產的減值虧損淨額		(20,917)	(9,943)
Other income and gains, net	其他收入及收益淨額	6	4,878	2,423
<b>Operating profit</b>			<b>287,327</b>	186,355
Finance costs, net	財務成本淨額	7	(3,827)	(4,903)
<b>Profit before income tax</b>			<b>283,500</b>	181,452
Income tax expenses	除所得稅前溢利 所得稅開支	9	(48,739)	(33,524)
<b>Profit from continuing operations</b>			<b>234,761</b>	147,928
Profit from discontinued operations	來自持續經營業務的溢利 來自已終止經營業務的溢利		-	9,395
<b>Profit for the period</b>			<b>234,761</b>	157,323
<b>Profit attributable to:</b>				
- Owners of the Company	以下人士應佔溢利： - 本公司擁有人		234,363	156,273
- Non-controlling interests	- 非控股權益		398	1,050
			<b>234,761</b>	157,323
<b>Other comprehensive income for the period, net of tax</b>				
Items that will not be reclassified to profit or loss:	期內其他全面收益，扣除稅項 不會重新分類至損益的項目：			
- Changes in fair value of financial assets designated at fair value through other comprehensive income, net of tax	- 指定為按公平值計入其他全面收益的金融資產的公平值變動，扣除稅項	15	-	1,652
<b>Total comprehensive income for the period</b>			<b>234,761</b>	158,975

## Interim Condensed Consolidated Statement of Comprehensive Income

### 中期簡明綜合全面收益表

		For six months ended June 30, 截至六月三十日止六個月	
		2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
		Note 附註	
<b>Total comprehensive income attributable to:</b>	以下各方應佔全面收益總額：		
- Owners of the Company	- 本公司擁有人		234,363
- Non-controlling interests	- 非控股權益		157,752
			398
			1,223
			<b>234,761</b>
			158,975
<b>Earnings per share for profit attributable to the owners of the Company for the period (RMB)</b>	期內本公司擁有人應佔溢利的每股盈利(人民幣)		
Basic and diluted	基本及攤薄	10	
- From continuing operations	- 來自持續經營業務		0.44
- From discontinued operations	- 來自已終止經營業務		-
			0.30
			0.02
			<b>0.44</b>
			0.32

The above interim condensed consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.

上述中期簡明綜合全面收益表應與隨附附註一併閱讀。

## Interim Condensed Consolidated Statement of Financial Position

### 中期簡明綜合財務狀況表

		Notes 附註	As at June 30, 2022 於二零二二年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	As at December 31, 2021 於二零二一年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
<b>Assets</b>	<b>資產</b>			
<b>Non-current assets</b>	<b>非流動資產</b>			
Property and equipment	物業及設備	11	641,875	485,200
Intangible assets	無形資產		3,749	5,675
Trade and other receivables and prepayments	貿易及其他應收款項以及預付款項	14	6,141	17,227
Financial assets at fair value through other comprehensive income ("FVOCI")	按公平值計入其他全面收益(「按公平值計入其他全面收益」)的金融資產	15	186,004	110,004
Financial assets at fair value through profit or loss ("FVTPL")	按公平值計入損益(「按公平值計入損益」)的金融資產	16	159,573	58,243
Deferred income tax assets	遞延所得稅資產		33,606	35,809
			<b>1,030,948</b>	712,158
<b>Current assets</b>	<b>流動資產</b>			
Inventories	存貨	13	74,229	41,697
Trade and other receivables and prepayments	貿易及其他應收款項及預付款項	14	1,559,492	869,717
Financial assets at FVTPL	按公平值計入損益的金融資產	16	121,183	-
Restricted cash	受限制現金	17	22,186	31,146
Cash and cash equivalents	現金及現金等價物	17	1,083,540	800,695
			<b>2,860,630</b>	1,743,255
<b>Total assets</b>	<b>總資產</b>		<b>3,891,578</b>	2,455,413
<b>Equity</b>	<b>權益</b>			
<b>Equity attributable to owners of the Company</b>	<b>本公司擁有人應佔權益</b>			
Share capital and premium	股本及溢價	20	791,374	21,126
Other reserves	其他儲備	21	955,382	955,382
Retained earnings	保留盈利		709,559	475,196
Non-controlling interests	非控股權益		274	(124)
<b>Total equity</b>	<b>總權益</b>		<b>2,456,589</b>	1,451,580



## Interim Condensed Consolidated Statement of Financial Position

### 中期簡明綜合財務狀況表

		Notes 附註	As at June 30, 2022 於二零二二年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	As at December 31, 2021 於二零二一年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
<b>Liabilities</b>	<b>負債</b>			
<b>Non-current liabilities</b>	<b>非流動負債</b>			
Borrowings	借款	19	192,106	82,363
Lease liabilities	租賃負債	12	50,374	44,162
Deferred income tax liabilities	遞延所得稅負債		6,470	6,470
			<b>248,950</b>	132,995
<b>Current liabilities</b>	<b>流動負債</b>			
Borrowings	借款	19	250,035	208,322
Trade and other payables	貿易及其他應付款項	18	855,226	556,663
Lease liabilities	租賃負債	12	19,723	27,171
Deferred revenue	遞延收益		6,750	6,750
Current income tax liabilities	即期所得稅負債		54,305	71,932
			<b>1,186,039</b>	870,838
<b>Total liabilities</b>	<b>總負債</b>		<b>1,434,989</b>	1,003,833
<b>Total equity and liabilities</b>	<b>權益及負債總額</b>		<b>3,891,578</b>	2,455,413

The above interim condensed consolidated statement of financial position should be read in conjunction with the accompanying notes.

The interim condensed consolidated financial statements on pages 45 to 80 were approved by the board of directors on August 11, 2022 and were signed on its behalf:

**Zhang Yong**  
張勇  
Director  
董事

上述中期簡明綜合財務狀況表應與隨附附註一併閱讀。

第45至80頁的中期簡明綜合財務報表已由董事會於2022年8月11日批准，並由以下人士代為簽署：

## Interim Condensed Consolidated Statement of Changes in Equity 中期簡明綜合權益變動表

		Attributable to owners of the Company 本公司擁有人應佔					Non- controlling interest 非控股權益 RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
		Share capital and share premium 股本及股份溢價 RMB'000 人民幣千元	Other reserves 其他儲備 RMB'000 人民幣千元	Retained earnings 保留盈利 RMB'000 人民幣千元	Subtotal 小計 RMB'000 人民幣千元			
	Notes 附註							
<b>Balance as at January 1, 2022 (Audited)</b>	於二零二二年一月一日的 結餘(經審核)	21,126	955,382	475,196	1,451,704	(124)	1,451,580	
Profit for the period	期內溢利	-	-	234,363	234,363	398	234,761	
<b>Total Comprehensive income for the period</b>	期內全面收益總額	-	-	234,363	234,363	398	234,761	
<b>Transactions with shareholders of the Company</b>	與本公司股東的交易							
Shares issued upon the completion of initial public offering, net of transaction costs	於完成首次公開發售後發行 股份，扣除交易成本	20	716,349	-	-	716,349	-	
Shares issued upon partial exercise of the over-allotment option, net of transaction costs	於部分行使超額配股權後發 行股份，扣除交易成本	20	53,899	-	-	53,899	-	
<b>Balance as at June 30, 2022 (Unaudited)</b>	於二零二二年六月三十日的 結餘(未經審核)	791,374	955,382	709,559	2,456,315	274	2,456,589	

## Interim Condensed Consolidated Statement of Changes in Equity 中期簡明綜合權益變動表

		Attributable to owners of the Company 本公司擁有人應佔					Non- controlling interest 非控股權益 人民幣千元	Total 總計 人民幣千元
		Share capital and share premium 股本及股份溢價 RMB'000 人民幣千元	Other reserves 其他儲備 RMB'000 人民幣千元	Retained earnings 保留盈利 RMB'000 人民幣千元	Subtotal 小計 RMB'000 人民幣千元			
		Note 附註						
<b>Balance as at January 1, 2021 (Audited)</b>	於二零二一年一月一日的 結餘(經審核)	1,395	954,899	91,614	1,047,908	18,476	1,066,384	
Profit for the period	期內溢利	-	-	156,273	156,273	1,050	157,323	
Other comprehensive income	其他全面收入							
- Changes in fair value of equity investments at FVOCI, net of tax	- 按公平值計入其他全面 收益的權益投資的公平值 變動, 扣除稅項	-	1,479	-	1,479	173	1,652	
<b>Total comprehensive income for the period</b>	<b>期內全面收益總額</b>	<b>-</b>	<b>1,479</b>	<b>156,273</b>	<b>157,752</b>	<b>1,223</b>	<b>158,975</b>	
Transaction with non-controlling interest	與非控股權益的交易	19,731	-	-	19,731	(19,731)	-	
<b>Balance as at June 30, 2021 (Unaudited)</b>	於二零二一年六月三十日的 結餘(未經審核)	21,126	956,378	247,887	1,225,391	(32)	1,225,359	

The above interim condensed consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

上述中期簡明綜合權益變動表應與隨附附註一併閱讀。



## Interim Condensed Consolidated Statement of Cash Flows 中期簡明綜合現金流量表

For six months ended June 30,  
截至六月三十日止六個月

			2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
		Note 附註		
<b>Cash flows of operating activities</b>	<b>經營活動現金流量</b>			
<b>Continuing operations</b>	<b>持續經營業務</b>			
Cash (used in)/generated from operations	經營(所用)/所得現金		(103,285)	23,588
PRC enterprise income tax paid	已付中國企業所得稅		(64,163)	(31,669)
<b>Net cash used in operating activities</b>	<b>經營活動所用現金淨額</b>		<b>(167,448)</b>	<b>(8,081)</b>
<b>Cash flows of investing activities</b>	<b>投資活動現金流量</b>			
<b>Continuing operations</b>	<b>持續經營業務</b>			
Refund of prepayments due to cancellation of the Health City Project	就取消健康城市項目的預付款項的退款		-	170,000
Prepayments for construction materials	建築材料的預付款項		-	98,000
Repayment of cash advance from a third party	償還來自第三方的現金墊款		-	62,700
Collection of cash advance from the Disposal Group	收取來自出售組別的現金墊款		19,750	-
Purchase of property and equipment	購買物業及設備		(169,471)	(47,266)
Purchase of financial assets at FVOCI	購買按公平值計入其他全面收益的金融資產		(82,000)	-
Purchase of financial assets at FVTPL	購買按公平值計入損益的金融資產		(222,513)	-
Proceeds from disposal of financial assets at FVTPL and FVOCI	出售按公平值計入其他全面收益及按公平值計入損益的金融資產所得款項		-	154,856
<b>Net cash (used in)/from investing activities</b>	<b>投資活動(所用)/所得現金淨額</b>		<b>(454,234)</b>	<b>438,290</b>

## Interim Condensed Consolidated Statement of Cash Flows

### 中期簡明綜合現金流量表

		For six months ended June 30, 截至六月三十日止六個月	
		2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
		Note 附註	
<b>Cash flows from financing activities</b>	<b>融資活動所得現金流量</b>		
<b><i>Continuing operations</i></b>	<b>持續經營業務</b>		
Proceeds from borrowings	借款所得款項		180,000
Repayments of borrowings	償還借款		(273,205)
Interest paid	已付利息		(8,604)
Principal elements and interests expenses of lease payments	租賃負債的本金部分及利息開支		(5,665)
Proceeds from initial public offering	首次公開發售所得款項		–
Proceeds from partial exercise of the over-allotment option	部分行使超額配股權所得款項		–
Listing expense paid	已付上市開支		(3,485)
Net cash from/(used in) financing activities	融資活動所得／(所用)現金淨額		(110,959)
Discontinued operations	已終止經營業務		27,854
Net increase in cash and cash equivalents	現金及現金等價物增加淨額		347,104
Cash and cash equivalents at beginning of the period	期初現金及現金等價物		335,835
Cash and cash equivalents at end of the period	期末現金及現金等價物	17	682,939

The above interim condensed consolidated statement of cash flows should be read in conjunction with the accompanying notes.

上述中期簡明綜合現金流量表應與隨附附註一併閱讀。

## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 1. GENERAL INFORMATION

The Company was incorporated in the Cayman Islands on July 20, 2018 as an exempted company with limited liability under the Companies Act, Cap. 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands. The address of the Company's registered office is P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman KY1-1205, Cayman Islands.

The Company is an investment holding company, and its subsidiaries, are primarily engaged in the provision of diagnostic testing services (the "Diagnostic Business" or the "Continuing Business") in China.

The shares of the Company (the "Shares") were listed on the Main Board of the Stock Exchange of Hong Kong Limited (the "Stock Exchange") on May 18, 2022 (the "Listing").

This interim condensed consolidated financial information is presented in RMB, unless otherwise stated. This interim condensed consolidated financial information has been approved for issue by the Board on August 11, 2022.

This interim condensed consolidated financial information has not been audited.

### 1. 一般資料

本公司於2018年7月20日根據開曼群島公司法第22章(1961年第3號法例, 經綜合及修訂)在開曼群島註冊成立為獲豁免有限公司。本公司的註冊辦事處地址為P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman KY1-1205, Cayman Islands。

本公司為一間投資控股公司, 且其附屬公司主要於中國從事提供診斷檢測服務(「診斷業務」或「持續經營業務」)。

本公司股份(「股份」)於2022年5月18日於香港聯合交易所有限公司(「聯交所」)主板上市(「上市」)。

除另有說明外, 本中期簡明綜合財務資料乃以人民幣呈列。本中期簡明綜合財務資料已由董事會於2022年8月11日批准刊發。

本中期簡明綜合財務資料未經審核。



## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 2. BASIS OF PREPARATION AND ACCOUNTING POLICIES

The interim financial information for the six months ended June 30, 2022 has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Hong Kong Stock Exchange Limited (the “Listing Rules”), including compliance with Hong Kong Accounting Standard 34 Interim Financial Reporting (“HKAS 34”), issued by the Hong Kong Institute of Certified Public Accountants (the “HKICPA”).

The Interim Financial Information does not include all the notes of the type normally included in an annual financial statement. Accordingly, it should be read in conjunction with the Group’s accountant’s report dated May 5, 2022 and any public announcements made by the Company during the Reporting Period.

The accounting policies applied to the preparation of the Interim Financial Information are consistent with those applied in the preparation of the accountant’s report of the Company for the years ended December 31, 2018, 2019, 2020 and 2021.

#### (a) Amended standards adopted by the Group

Amendments to Accounting Guideline 5	Merger Accounting for Common Control Combinations	January 1, 2022
Amendments to HKFRS 3	Reference to the Conceptual Framework	January 1, 2022
Amendments to HKAS 16	Property, Plant and Equipment Proceeds before Intended Use	January 1, 2022
Amendments to HKAS 37	Onerous Contracts – Costs of Fulfilling a Contract	January 1, 2022
Annual Improvements	Annual Improvements to HKFRS Standards 2018-2020 Cycle	January 1, 2022

The adoption of the new and amended standards which are effective for annual reporting period commencing January 1, 2022 does not have any significant impact on the Group’s Interim Financial Information.

### 2. 編製基準及會計政策

截至2022年6月30日止六個月的中期財務資料已根據香港聯合交易所有限公司證券上市規則（「上市規則」）的適用披露條文編製，包括遵守香港會計師公會（「香港會計師公會」）頒佈的香港會計準則第34號中期財務報告（「香港會計準則第34號」）。

中期財務資料並無包括一般載入年度財務報表的全部附註類型。因此，中期財務資料應與本集團日期為2022年5月5日的會計師報告及本公司於報告期間作出的任何公告一併閱讀。

編製中期財務資料所應用的會計政策與編製本公司截至2018年、2019年、2020年及2021年12月31日止年度的會計師報告所應用者一致。

#### (a) 本集團採納的經修訂準則

會計指引第5號（修訂）	共同控制下合併的合併會計法	2022年1月1日
香港財務報告準則第3號（修訂）	概念框架提述	2022年1月1日
香港會計準則第16號（修訂）	作擬定用途之前的物業、廠房及設備所得款項	2022年1月1日
香港會計準則第37號（修訂）	虧損合約 – 履行合約成本	2022年1月1日
年度改進	香港財務報告準則2018年至2020年週期的年度改進	2022年1月1日

採用於2022年1月1日開始年度報告期間生效的新訂及經修訂準則對本集團的中期財務資料並無任何重大影響。

## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 2. BASIS OF PREPARATION AND ACCOUNTING POLICIES

(Continued)

#### (b) New standards, amendments, interpretation and accounting guideline not yet adopted

The following new standards, amendments, interpretation to standards and accounting guideline have been issued but are not effective for the financial period beginning on or after July 1, 2022 and have not been early adopted:

### 2. 編製基準及會計政策 (續)

#### (b) 尚未採納的新訂準則、修訂、詮釋及會計指引

於2022年7月1日或之後開始的財政期間已頒佈但未生效且尚未提早採納的新訂準則、修訂、準則的修訂及會計指引如下：

		Effective for annual periods beginning on or after 於以下日期或 之後開始的 年度期間生效
Amendments to HKAS 12 香港會計準則第12號 (修訂)	Deferred Tax related to Assets and Liabilities arising from a Single Transaction 與單一交易產生的資產及負債有關的遞延稅項	January 1, 2023 2023年1月1日
Amendments to HKAS 8 香港會計準則第8號 (修訂)	Definition of Accounting Estimates 會計估計的定義	January 1, 2023 2023年1月1日
Amendments to HKAS 1 and HKFRS Practice Statement 2 香港會計準則第1號及香港財務報告準則實務公告第2號 (修訂)	Disclosure of Accounting Policies 會計政策披露	January 1, 2023 2023年1月1日
HKFRS 17 and Amendments to HKFRS 17 香港財務報告準則第17號及香港財務報告準則第17號 (修訂)	Insurance Contract 保險合約	January 1, 2023 2023年1月1日
HK Interpretation 5 香港詮釋第5號	Classification by the Borrower of a Term Loan that Contains a Repayment on Demand Clause 借款人對載有按要求償還條款之定期貸款之分類	January 1, 2023 2023年1月1日
Amendments to HKAS 1 香港會計準則第1號 (修訂)	Classification of Liabilities as Current or Non-current 分類為流動或非流動負債	January 1, 2024 2024年1月1日
Amendments to HKFRS 10 and HKAS 28 香港財務報告準則第10號及香港會計準則第28號 (修訂)	Sale or Contribution of Assets between an Investor and its Associate or Joint Ventures 投資者與其聯營公司或合資企業之間的資產出售或注資	To be determined 待釐定

## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 2. BASIS OF PREPARATION AND ACCOUNTING POLICIES

(Continued)

#### (b) New standards, amendments, interpretation and accounting guideline not yet adopted (Continued)

The above new and amended standards, interpretation and accounting guideline are effective for annual periods beginning on or after January 1, 2023 and have not been early adopted by the Group. The Group has already commenced an assessment of the impact of these new or amended standards, interpretation and annual improvements. According to the preliminary assessment made by the Group, no significant impact on the financial performance and position of the Group is expected when the aforesaid new or amended standards, interpretations and annual improvements become effective.

### 3. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENT

The preparation of the Interim Financial Information in accordance with HKAS 34 requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates.

In preparing the Interim Financial Information, the significant judgements made by management in apply the Group's accounting policies and the key sources of estimation uncertainty were the same as those applied in the accountant's report of the Company for the years ended December 31, 2018, 2019, 2020 and 2021.

### 2. 編製基準及會計政策 (續)

#### (b) 尚未採納的新訂準則、修訂、詮釋及會計指引 (續)

上述新訂及經修訂準則、詮釋及會計指引於2023年1月1日或之後開始的年度期間生效，惟未獲本集團提早採用。本集團已經開始評估該等新訂或經修訂準則、詮釋及年度改進的影響。根據本集團作出的初步評估，上述新訂或經修訂準則、詮釋及年度改進生效時並無對本集團財務表現及狀況造成重大影響。

### 3. 重要會計估計及判斷

根據香港會計準則第34號編製的中期財務資料需要管理層作出判斷、估計及假設，對會計政策應用，以及資產及負債、收入及開支的報告金額有所影響。實際結果可能有別於該等估計。

於編製中期財務資料時，管理層於應用本集團的會計政策及估計不確定性的主要來源所作出的重要判斷與本公司截至2018年、2019年、2020年及2021年12月31日止年度的會計師報告所應用者相同。



## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 4. FAIR VALUE ESTIMATION

The Group made judgements and estimates in determining the fair values of the financial instruments that are recognised and measured at fair value in the financial statement. To provide an indication about the reliability of the inputs used in determining fair value, the Group has classified its financial instruments into the three levels prescribed under the accounting standards.

The Group's policy is to recognise transfers into and transfers out of fair value hierarchy levels as at the end of the reporting period.

**Level 1:** The fair value of financial instruments traded in active markets is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the Group is the current bid price. These instruments are included in level 1.

**Level 2:** The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

**Level 3:** If one or more of the significant inputs are not based on observable market data, the instrument is included in level 3.

As at June 30, 2022 and December 31, 2021, the Group had no level 1 and level 2 financial instruments and had level 3 instruments which are the Group's financial assets designated at FVOCI (Note 15) and financial assets designated at FVTPL (Note 16), respectively.

There were no transfers between levels 1, 2 and 3 for recurring fair value measurements during the six months ended June 30, 2022 and June 30, 2021.

### 4. 公平值估計

本集團就釐定於財務報表內須以公平值進行確認及計量的金融工具的公平值作出判斷及估計。為得出釐定公平值所用輸入數據的可信程度指標，本集團根據會計準則將其金融工具分為三個層級。

本集團的政策是於報告期末確認公平值層級的轉入與轉出。

**第1級：** 於交投活躍市場買賣之金融工具之公平值根據報告期末之市場報價計算。本集團所持金融資產所用之市場報價為當時買盤價。該等工具會被列為第1級。

**第2級：** 非於活躍市場買賣之金融工具之公平值以估值技術計算，該等估值方法充分利用可觀察市場數據，並盡量減少依賴實體之特有估計數據。倘按公平值計量之工具的所有重大數據均可從觀察取得，則該項工具會被列為第2級。

**第3級：** 倘一個或多個重大輸入數據並非根據可觀察市場數據釐定，則該項工具會被列為第3級。

於2022年6月30日及2021年12月31日，本集團未擁有第1級及第2級金融工具，而分別擁有指定為按公平值計入其他全面收益（附註15）及按公平值計入損益（附註16）的本集團金融資產的第3級工具。

截至2022年6月30日及2021年6月30日止六個月，經常性公平值計量在第1級、第2級及第3級之間無轉移。

## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 4. FAIR VALUE ESTIMATION (Continued)

#### (a) Valuation process, inputs and relationship to fair value

The Group has a team that manages the valuation of level 3 instruments for financial reporting purposes. The team manages the valuation exercise of the investments on a case by case basis. The team uses valuation techniques to determine the fair value of the Group's level 3 instruments. External valuation experts will be involved when necessary.

As these instruments are not traded in an active market, their fair values have been determined by using various applicable valuation techniques, including:

- the latest round financing, i.e. the prior transaction price or the third-party pricing information; and
- a combination of observable and unobservable inputs, including risk-free rate, expected volatility, discount rate for lack of marketability, market multiples, etc.

During the six months ended June 30, 2022, the fair value changes on financial assets measured at FVOCI and FVTPL are considered as immaterial.

### 4. 公平值估計(續)

#### (a) 估值過程、輸入數據及與公平值的關係

本集團擁有一支管理第3級工具估值以作財務報告用途的團隊。該團隊按個別情況管理該等投資的估值行使情況。該團隊使用估值方法確定本集團第3級工具的公平值。如有需要，外聘估值專家將參與其中。

由於該等工具並無於活躍市場買賣，其公平值乃透過使用各種適用估值方法釐定，包括：

- 最新一輪融資，即過往交易價格或第三方定價資料；及
- 結合可觀察及不可觀察輸入數據，包括無風險利率、預期波幅、缺乏市場性的貼現率、市場倍數等。

截至2022年6月30日止六個月，按公平值計入其他全面收益及按公平值計入損益計量的金融資產公平值變動被視為不重大。

## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 5. REVENUE AND SEGMENT INFORMATION

#### (a) Segment information

Management has determined the operating segments based on the reports reviewed by the chief operating decision maker (“CODM”). The CODM, who is responsible for allocating resources and assessing performance of the operating segment, has been identified as the executive directors of the Company.

During the six months ended June 30, 2022, the Group is principally engaged in the provision of diagnosis testing to hospital and non-medical clients. Management reviews the operating results of the business as one operating segment to make decisions about resources to be allocated. Therefore, the CODM of the Company regards that there is only one segment which is used to make strategic decisions.

The principal operating entities of the Group are domiciled in the PRC. Accordingly, all of the Group’s revenue were derived in the PRC during the six months ended June 30, 2022 and 2021.

As at June 30, 2022 and December 31, 2021, all of the non-current assets of the Group were located in the PRC.

#### (b) Revenue by customer type

<i>Recognised at a point in time</i>	<i>在某一時間點確認</i>
Diagnostic outsourcing services	診斷外包服務
Diagnostic testing services for medical institution alliances	為醫聯體提供的診斷檢測服務
Diagnostic testing services for non-medical institutions	為非醫療機構提供的診斷檢測服務

	<b>680,362</b>	483,209
	<b>650,700</b>	244,449
	<b>47,594</b>	30,372
	<b>1,378,656</b>	758,030

### 5. 收益及分部資料

#### (a) 分部資料

管理層已根據主要經營決策者（「主要經營決策者」）審閱的報告確定經營分部。主要經營決策者經確定為本公司的執行董事，負責分配資源及評估經營分部的表現。

截至2022年6月30日止六個月，本集團主要從事向醫院及非醫療客戶提供診斷檢測。管理層將該項業務作為一個經營分部，審閱其經營業績，以就資源分配作出決策。因此，本公司的主要經營決策者認為僅有一個可用於作出戰略性決策的分部。

本集團的主要經營實體位於中國，故本集團於截至2022年及2021年6月30日止六個月的全部收益均來自中國。

於2022年6月30日及2021年12月31日，本集團的所有非流動資產均位於中國。

#### (b) 按客戶類別劃分的收益

**For six months ended June 30,**  
截至六月三十日止六個月

2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
--	--



## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 5. REVENUE AND SEGMENT INFORMATION (Continued)

#### (c) Information about major customers

All the revenues derived from single external customers were less than 10% of the Group's total revenues during the interim reporting period (2021: same).

#### (d) Unsatisfied performance obligations

For diagnostic testing services, they are rendered in short period of time, which is generally within hours or a couple of days, which unsatisfied performance obligations are immaterial and the Group has elected the practical expedient for not to disclose the remaining performance obligations for these types of contracts.

### 6. OTHER INCOME AND GAINS-NET

### 5. 收益及分部資料 (續)

#### (c) 主要客戶資料

於中期報告期間，來自單個外部客戶的所有收益低於本集團總收益的10% (2021年：相同)。

#### (d) 未履行的履約義務

就診斷檢測服務而言，該等服務提供時間短，通常於數小時內或數天內。該等未履行的履約義務並不重大，且本集團已選擇實際權宜之計，以致毋須披露該等類型合約的剩餘履約義務。

### 6. 其他收入及收益－淨額

For six months ended June 30,  
截至六月三十日止六個月

		2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Government grants (a)	政府補助(a)	5,068	2,092
Loss on disposal of equipment	出售設備虧損	(40)	(39)
Fair value gains of FVTPL-net	按公平值計入損益的 公平值收益－淨額	-	765
Others	其他	(150)	(395)
		<b>4,878</b>	<b>2,423</b>

(a) The government grants include those grants from the local government in recognition of the entitlement of high and new technology enterprises, and the hospital contribution to local economy's development. There are no unfulfilled conditions or other contingencies attached to these grants.

(a) 政府補助包括地方政府為確認高新技術企業的資格，及醫院對當地經濟發展的貢獻而發放的補助。該等補助並無附帶未達成條件或其他或然事項。

## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 7. FINANCE COSTS-NET

		For six months ended June 30, 截至六月三十日止六個月	
		2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
<b>Finance costs-net</b>	<b>財務成本－淨額</b>		
Interest income from bank deposits	銀行存款利息收入	(4,153)	(4,223)
Interest expenses on borrowings	借款利息開支	6,319	8,604
Interest on lease liabilities	租賃負債利息	1,661	522
		<b>3,827</b>	4,903

### 7. 財務成本－淨額

For six months ended June 30,  
截至六月三十日止六個月

2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
--	--

### 8. EXPENSES BY NATURES

The major items of the expenses by nature are listed as below:

		For six months ended June 30, 截至六月三十日止六個月	
		2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Cost of reagent and pharmaceuticals consumed	所耗用的試劑及藥品成本	420,546	203,769
Staff costs	員工成本	200,854	113,166
Subcontracting costs	分包成本	125,638	57,935
Marketing and promotion expenses	營銷及推廣開支	106,442	81,091
Depreciation and amortization charges	折舊及攤銷費用	81,976	24,313
Transportation expenses	運輸開支	43,184	21,422
Listing expenses	上市開支	27,483	17,459
Traveling and entertainment expenses	差旅及娛樂開支	24,525	18,391

### 8. 按性質劃分的開支

按性質劃分的開支主要項目列示如下：

For six months ended June 30,  
截至六月三十日止六個月

2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
--	--

## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 9. INCOME TAX EXPENSES

### 9. 所得稅開支

		For six months ended June 30, 截至六月三十日止六個月	
		2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Current income tax	即期所得稅	52,890	35,494
Deferred income tax	遞延所得稅	(4,151)	(1,970)
		<b>48,739</b>	<b>33,524</b>

The Group's principal applicable taxes and tax rates are as follows:

#### Cayman Islands

Under the prevailing laws of the Cayman Islands, the Company is not subject to tax on income or capital gains. In addition, no Cayman Islands withholding tax is payable on dividend payments by the Company to its shareholders.

#### Hong Kong

Under the two-tiered profits tax regime, Hong Kong Profits Tax rate is 8.25% for assessable profits on the first HK\$2 million and 16.5% for any assessable profits in excess. No Hong Kong Profits Tax was provided for as there was no estimated assessable profits that was subject to Hong Kong Profits Tax during the interim reporting period.

#### PRC Corporate Income Tax ("CIT")

CIT was made on the estimated assessable profits of the entities within the Group incorporated in the PRC and was calculated in accordance with the relevant tax rules and regulations of the PRC after considering the available tax refunds and allowances. The general CIT rate is 25% for the six months ended June 30, 2022 and 2021.

本集團的主要適用稅項及稅率如下：

#### 開曼群島

根據開曼群島現行法律，本公司毋須就收入或資本收益繳納稅項。此外，本公司派付予其股東的股息毋須繳納開曼群島預扣稅。

#### 香港

根據兩級制利得稅制度，香港利得稅按首2百萬港元應課稅溢利以8.25%的稅率徵稅，超出2百萬港元部分的任何應課稅溢利按16.5%的稅率徵稅。由於中期報告期間並無須繳納香港利得稅的估計應課稅溢利，故並無就香港利得稅計提撥備。

#### 中國企業所得稅（「企業所得稅」）

企業所得稅乃根據中國相關稅務規則及規例，經考慮可供使用的退稅及免稅額，按本集團於中國註冊成立的實體的估計應課稅溢利繳納。截至2022年及2021年6月30日止六個月，一般企業所得稅率為25%。



## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 9. INCOME TAX EXPENSES (Continued)

#### PRC Corporate Income Tax (“CIT”) (Continued)

Certain entities within the Group, which generated most of the Group’s profits, have been approved as high technology enterprises under the relevant tax rules and regulations, and accordingly, are subjected to a reduced preferential CIT rate of 15% during the periods presented.

Certain of the Group’s entities in PRC meet the standards for small enterprises under the relevant tax rules and regulations, and are subjected to a preferential CIT rate.

### 10. EARNINGS PER SHARE

#### (a) Basic earnings per share

The basic earnings per share is calculated by dividing the profit attributable to owners of the Company by the weighted average number of ordinary shares in issue during the six months ended June 30, 2022 and 2021. In determining the weighted average number of ordinary shares in issued, the share subdivision effective upon the Listing was deemed to have been in issue since January 1, 2021 which has been reflected in the calculations of the basic and diluted earnings per share.

### 9. 所得稅 (續)

#### 中國企業所得稅 (「企業所得稅」) (續)

根據相關稅務規則及規例，本集團內若干實體（為本集團創造大部分溢利）已獲認定為高科技企業，因此，於呈報期間，該等集團實體可享15%的已降低優惠企業所得稅率。

根據相關稅務規則及規例，中國境內的若干本集團實體符合小型企業標準，因此，可享優惠企業所得稅率。

### 10. 每股盈利

#### (a) 每股基本盈利

每股基本盈利按本公司擁有人應佔溢利除以截至2022年及2021年6月30日止六個月已發行普通股的加權平均數計算。於釐定已發行普通股的加權平均數時，於上市時生效的股份拆細被視為自2021年1月1日起已發行，並已反映於每股基本及攤薄盈利計算中。

#### For six months ended June 30, 截至六月三十日止六個月

	2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Profit attributable to owners of the Company 本公司擁有人應佔溢利		
– From continuing operations – 來自持續經營業務	<b>234,363</b>	147,041
– From discontinued operations – 來自已終止經營業務	–	9,232
	<b>234,363</b>	156,273

## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 10. EARNINGS PER SHARE (Continued)

#### (a) Basic earnings per share (Continued)

		For six months ended June 30, 截至六月三十日止六個月	
		2022 二零二二年 (Unaudited) (未經審核)	2021 二零二一年 (Unaudited) (未經審核)
Weighted average number of ordinary shares in issue	已發行普通股的加權平均數	527,710,850	497,048,111
Basic earnings per share attributable to the owners of the Company (RMB)	本公司擁有人應佔每股基本盈利(人民幣)		
- From continuing operations	- 來自持續經營業務	0.44	0.30
- From discontinued operations	- 來自已終止經營業務	-	0.02
		0.44	0.32

#### (b) Diluted earnings per share

Diluted earnings per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares.

The Company had no dilutive potential shares in issue, thus the diluted earnings per share for six months ended June 30, 2022 and 2021 are the same as basic earnings per share of the respective periods.

### 10. 每股盈利(續)

#### (a) 每股基本盈利(續)

#### (b) 每股攤薄盈利

每股攤薄盈利乃經假設已轉換所有具攤薄潛力的普通股而對已發行普通股的加權平均數作出調整計算。

本公司並無已發行潛在攤薄股份，因此截至2022年及2021年6月30日止六個月的每股攤薄盈利與各期內每股基本盈利相同。

**Notes to the Interim Condensed Consolidated Financial Statements**  
**中期簡明綜合財務報表附註**

**11. PROPERTY AND EQUIPMENT**

**11. 物業及設備**

		<b>Property and equipment 物業及設備 RMB'000 人民幣千元</b>	<b>Right-of- use assets 使用權資產 RMB'000 人民幣千元</b>	<b>Total 總計 RMB'000 人民幣千元</b>
For six months ended June 30, 2022 (Unaudited)	截至二零二二年 六月三十日止六個月 (未經審核)			
At January 1, 2022 (audited)	於二零二二年一月一日 (經審核)	273,955	211,245	485,200
Additions	添置	220,335	18,707	239,042
Disposals	出售	(143)	-	(143)
Depreciation charge	折舊支出	(69,702)	(12,522)	(82,224)
At June 30, 2022 (unaudited)	於二零二二年六月三十日 (未經審核)	424,445	217,430	641,875
For six months ended June 30, 2021 (Unaudited)	截至二零二一年 六月三十日止六個月 (未經審核)			
At January 1, 2021 (audited)	於二零二一年一月一日 (經審核)	107,430	169,622	277,052
Additions	添置	42,057	9,210	51,267
Disposals	出售	(4,001)	-	(4,001)
Depreciation charge	折舊支出	(15,682)	(7,447)	(23,129)
At June 30, 2021 (unaudited)	於二零二一年六月三十日 (未經審核)	129,804	171,385	301,189



## Notes to the Interim Condensed Consolidated Financial Statements

### 中期簡明綜合財務報表附註

#### 12. LEASES

#### 12. 租賃

		As at June 30, 2022 於二零二二年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	As at December 31, 2021 於二零二一年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
<b>Right-of-use assets included in "Property and equipment"</b>	計入「物業及設備」 的使用權資產		
– Land use right	– 土地使用權	150,930	153,104
– Leased properties, equipment and motor vehicles	– 租賃物業、設備及 機動車輛	66,500	58,141
		<b>217,430</b>	211,245
<b>Lease liabilities</b>	租賃負債		
– Non-current	– 非流動	50,374	44,162
– Current	– 流動	19,723	27,171
		<b>70,097</b>	71,333

#### 13. INVENTORIES

#### 13. 存貨

		As at June 30, 2022 於二零二二年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	As at December 31, 2021 於二零二一年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Reagent and pharmaceuticals	試劑及藥品	74,229	41,697

**Notes to the Interim Condensed Consolidated Financial Statements**  
**中期簡明綜合財務報表附註**

**14. TRADE AND OTHER RECEIVABLES AND PREPAYMENTS**

**14. 貿易及其他應收款項以及預付款項**

		<b>As at June 30, 2022</b>	<b>As at December 31, 2021</b>
		於二零二二年 六月三十日	於二零二一年 十二月三十一日
		<b>RMB'000</b>	<b>RMB'000</b>
		人民幣千元	人民幣千元
		<b>(Unaudited)</b>	<b>(Audited)</b>
		(未經審核)	(經審核)
Trade receivables	貿易應收款項		
– Third parties	– 第三方	<b>1,608,415</b>	877,604
– Related parties	– 關聯方	<b>325</b>	323
		<b>1,608,740</b>	877,927
(Less): impairment loss allowance	(減): 減值虧損撥備	<b>(73,262)</b>	(52,626)
		<b>1,535,478</b>	825,301
Deposits	按金	<b>11,074</b>	7,470
Prepayments	預付款項	<b>9,669</b>	29,746
Amounts due from related parties	應收關聯方款項	<b>4,346</b>	21,220
Cash advance receivable	應收現金墊款	<b>2,721</b>	1,418
Tax recoverable	可收回稅項	<b>2,103</b>	1,966
Others	其他	<b>700</b>	–
		<b>30,613</b>	61,820
(Less): impairment loss allowance	(減): 減值虧損撥備	<b>(458)</b>	(177)
		<b>30,155</b>	61,643
		<b>1,565,633</b>	886,944
<b>Trade and other receivables and prepayments analyzed as:</b>	<b>貿易及其他應收款項以及預付款項分析為:</b>		
Current	流動	<b>1,559,492</b>	869,717
Non-current	非流動	<b>6,141</b>	17,227
		<b>1,565,633</b>	886,944

## Notes to the Interim Condensed Consolidated Financial Statements

### 中期簡明綜合財務報表附註

#### 14. TRADE AND OTHER RECEIVABLES AND PREPAYMENTS

(Continued)

- (a) The ageing of trade receivables, based on invoice date at the end of each reporting period is as follows:

Up to 180 days	最多180天
181 days to 1 year	181天至1年
1 to 2 years	1年至2年
2 to 3 years	2年至3年
More than 3 years	超過3年

- (b) The Group's trade and other receivables were denominated in RMB and their carrying amounts approximated their fair values.

#### 14. 貿易及其他應收款項以及預付款項 (續)

- (a) 下表載列於各報告期末貿易應收款項基於發票日期的賬齡分析：

		As at June 30, 2022 於二零二二年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	As at December 31, 2021 於二零二一年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
		1,111,174	628,062
		368,247	154,530
		92,341	70,528
		15,435	12,713
		21,543	12,094
		<b>1,608,740</b>	877,927

- (b) 本集團的貿易及其他應收款項以人民幣計值，且其賬面值與公平值相若。



## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 15. FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

The Group's financial assets at FVOCI included equity investments which are not held for trading, and which the Group has irrevocably elected at initial recognition to recognise in this category. These are strategic investments and the Group considers this classification to be more relevant.

Unlisted equity investments

非上市權益投資

186,004

110,004

The table below shows the gains as recognised in other comprehensive income:

Gains recognised in other comprehensive income

於其他全面收益內確認的收益

–

2,202

(Less): income tax impact

(減): 所得稅影響

–

(550)

–

1,652

Information about the methods and assumption used in determining fair value have been set out in Note 4.

### 15. 按公平值計入其他全面收益的金融資產

本集團按公平值計入其他全面收益的金融資產包括並非持作買賣之權益投資，且本集團於初步確認時不可撤銷地選擇於此類別確認。該等投資為戰略投資，且本集團認為此分類更有相關性。

As at June 30, 2022 於二零二二年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	As at December 31, 2021 於二零二一年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
186,004	110,004

下表載列於其他全面收益內確認的收益：

For six months ended June 30, 截至六月三十日止六個月	
2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
–	2,202
–	(550)
–	1,652

有關釐定公平值所用的方法及假設的資料載於附註4。

## Notes to the Interim Condensed Consolidated Financial Statements

### 中期簡明綜合財務報表附註

#### 16. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

The Group's financial assets at FVTPL comprised debt investments and equity investments that do not qualify for measurement at either amortised cost or FVOCI.

#### 16. 按公平值計入損益的金融資產

本集團按公平值計入損益的金融資產包括不符合按攤銷成本或按公平值計入其他全面收益計量的債務投資及權益投資。

		As at June 30, 2022 於二零二二年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	As at December 31, 2021 於二零二一年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Unlisted equity investments	非上市權益投資	159,573	58,243
Wealth management product	理財產品	121,183	-
		<b>280,756</b>	58,243

The table below shows the gains as recognised in profit or loss:

下表載列於損益內確認的收益：

		For six months ended June 30, 截至六月三十日止六個月	
		2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Fair value gains recognised in profit or loss	於損益內確認的公平值收益	-	765

Information about the methods and assumption used in determining fair value have been set out in Note 4.

有關釐定公平值所用的方法及假設的資料載於附註4。

**Notes to the Interim Condensed Consolidated Financial Statements**  
**中期簡明綜合財務報表附註**

**17. CASH AND CASH EQUIVALENTS**

**17. 現金及現金等價物**

		<b>As at June 30, 2022</b>	<b>As at December 31, 2021</b>
		於二零二二年 六月三十日 <b>RMB'000</b> 人民幣千元 <b>(Unaudited)</b> (未經審核)	於二零二一年 十二月三十一日 <b>RMB'000</b> 人民幣千元 <b>(Audited)</b> (經審核)
Cash at banks and in hand	銀行及手頭現金		
– HKD	– 港元	<b>599,506</b>	–
– RMB	– 人民幣	<b>506,171</b>	831,821
– USD	– 美元	<b>49</b>	20
		<b>1,105,726</b>	831,841
(Less): restricted cash (a)	(減): 受限制現金(a)	<b>(22,186)</b>	(31,146)
Cash and cash equivalents	現金及現金等價物	<b>1,083,540</b>	800,695

(a) Restricted cash are all denominated in RMB. The restricted cash were deposited with banks as guarantee of performance obligations of the purchase of land-use-right.

(a) 受限制現金均以人民幣計值。受限制現金存放於銀行，為購買土地使用權履約責任擔保。



## Notes to the Interim Condensed Consolidated Financial Statements

### 中期簡明綜合財務報表附註

#### 18. TRADE AND OTHER PAYABLES

#### 18. 貿易及其他應付款項

		As at June 30, 2022 於二零二二年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	As at December 31, 2021 於二零二一年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
<b>Trade Payables</b>	<b>貿易應付款項</b>		
– Third parties	– 第三方	295,624	168,369
– Related parties	– 關聯方	329,341	192,175
		<b>624,965</b>	360,544
<b>Other payables</b>	<b>其他應付款項</b>		
– Accruals	– 應計費用	201,969	163,548
– Government grants received on behalf of joint applicants	– 代表聯名申請人收取的政府補助	1,272	7,396
– Unpaid consideration of FVOCI	– 按公平值計入其他全面收益的未付代價	–	6,000
– Others	– 其他	27,020	19,175
		<b>230,261</b>	196,119
		<b>855,226</b>	556,663

(a) The ageing of trade payables based on goods and services received is as follows:

(a) 貿易應付款項基於已收商品及服務的賬齡分析如下：

		As at June 30, 2022 於二零二二年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	As at December 31, 2021 於二零二一年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Up to 180 days	最多180天	407,896	279,984
181 days to 1 year	181天至1年	144,450	72,811
1 to 2 years	1年至2年	66,694	6,942
2 to 3 years	2年至3年	5,154	216
More than 3 years	超過3年	771	591
		<b>624,965</b>	360,544

(b) The Group's trade and other payables were denominated in RMB and their carrying amounts approximated their fair values.

(b) 本集團的貿易及其他應付款項以人民幣計值，且其賬面值與公平值相若。

**Notes to the Interim Condensed Consolidated Financial Statements**  
**中期簡明綜合財務報表附註**

**19. BORROWINGS**

**19. 借款**

		<b>As at June 30, 2022</b>	<b>As at December 31, 2021</b>
		於二零二二年 六月三十日	於二零二一年 十二月三十一日
		<b>RMB'000</b>	<b>RMB'000</b>
		人民幣千元	人民幣千元
		<b>(Unaudited)</b>	<b>(Audited)</b>
		(未經審核)	(經審核)
<b>Borrowings included in non-current liabilities</b>	計入非流動負債的借款		
Bank borrowings – Guaranteed (a)	銀行借款 – 有擔保(a)	<b>154,015</b>	69,900
Other borrowings	其他借款	<b>47,346</b>	50,785
Less: current portion of non-current borrowings	減：非流動借款的即期部分	<b>(9,255)</b>	(38,322)
		<b>192,106</b>	82,363
<b>Borrowings included in current liabilities</b>	計入流動負債的借款		
Bank borrowings – Guaranteed (a)	銀行借款 – 有擔保(a)	<b>240,780</b>	170,000
Add: current portion of non-current borrowings	加：非流動借款的即期部分	<b>9,255</b>	38,322
		<b>250,035</b>	208,322
<b>Total borrowings</b>	<b>借款總額</b>	<b>442,141</b>	290,685

The effective interest rate of the borrowings as at June 30, 2022 was 3.73% per annum (December 31, 2021: 4.28% per annum).

於2022年6月30日，借款的實際年利率為3.73%（2021年12月31日：年利率4.28%）。

(a) The secured and guarantee situations of the bank and other borrowings are as follows:

(a) 銀行及其他借款的抵押及擔保情況如下：

		<b>As at June 30, 2022</b>	<b>As at December 31, 2021</b>
		於二零二二年 六月三十日	於二零二一年 十二月三十一日
		<b>RMB'000</b>	<b>RMB'000</b>
		人民幣千元	人民幣千元
		<b>(Unaudited)</b>	<b>(Audited)</b>
		(未經審核)	(經審核)
<b>Bank borrowings</b>	銀行借款		
Guaranteed by subsidiaries of the Group	由本集團附屬公司擔保	<b>394,795</b>	239,900
<b>Other borrowings</b>	其他借款		
Guaranteed by Da An Group	由達安集團擔保	<b>39,000</b>	39,000
Guaranteed by subsidiaries of the Group	由本集團附屬公司擔保	<b>8,346</b>	11,785
		<b>47,346</b>	50,785

## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 20. SHARE CAPITAL AND SHARE PREMIUM

### 20. 股本及股份溢價

		Number of ordinary shares 普通股數量	Share capital 股本 RMB 人民幣元	Share premium 股份溢價 RMB 人民幣元	Total 總計 RMB 人民幣元
Balance at December 31, 2021 and January 1, 2022 (Audited)	於二零二一年十二月三十一日及 二零二二年一月一日的結餘 (經審核)	9,999,990	7,067	21,119,289	21,126,356
Effect of the share subdivision (a)	股份拆細的影響(a)	489,999,510	-	-	-
Effect of the share issues (b)	股份發行的影響(b)				
- Shares issued upon the completion of initial public offering, net of listing expenses	- 於完成首次公開發售後發行股 份，扣除上市開支	113,188,500	1,526	716,347,023	716,348,549
- Shares issued upon partial exercise of the over-allotment option, net of listing expenses	- 於部分行使超額配股權後發行 股份，扣除上市開支	8,062,500	108	53,899,414	53,899,522
		121,251,000	1,634	770,246,437	770,248,071
<b>Balance at June 30, 2022 (Unaudited)</b>	於二零二二年六月三十日的結餘 (未經審核)	<b>621,250,500</b>	<b>8,701</b>	<b>791,365,726</b>	<b>791,374,427</b>

- (a) Immediately prior to the Listing, a share subdivision was approved by the shareholders of the Company, pursuant to which, each issued and unissued share capital was subdivided into fifty shares with par value US\$0.000002 each. The share subdivision has been completed and became effective on May 18, 2022.
- (b) On May 18, 2022, the Company issued 113,188,500 new shares at the price of HK\$7.89 per share as a result of the completion of the global offering (the "Global Offering"). 8,062,500 shares were issued upon the exercise of the over-allotment option in connection with the Global Offering on June 10, 2022 at the same price. Gross proceeds from the issue amounted to HKD956,670,390 (equivalent to RMB821,779,031). After deducting the underwriting fees and other capitalised listing expenses, net proceeds from the issue amounted to RMB770,248,071, of which, RMB1,634 was recorded as share capital and RMB770,246,437 was recorded as share premium.

- (a) 於緊接上市前，本公司股東批准股份拆細，據此，每股已發行及未發行股本拆細為五十股每股面值0.000002美元的股份。股份拆細已於2022年5月18日完成及生效。
- (b) 於2022年5月18日，本公司因完成全球發售（「全球發售」）而以每股7.89港元的價格發行113,188,500股新股份。於2022年6月10日按相同價格行使與全球發售有關的超額配股權後發行8,062,500股股份。發行所得款項總額為956,670,390港元（相當於人民幣821,779,031元）。經扣除包銷費用及其他資本化上市開支後，發行所得款項淨額為人民幣770,248,071元，其中人民幣1,634元入賬列作股本及人民幣770,246,437元入賬列作股份溢價。



## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 21. OTHER RESERVES AND DIVIDENDS

#### (a) Other reserves

The Group's other reserves comprise capitalisation reserves and reserves for financial assets at FVOCI.

Capitalisation reserves represented the capital and capital premium of Yunkang Health Industry Investment Co., Ltd. ("Yunkang Industry") attributable to the owners of the Company in aggregate of approximately RMB931 million as of January 1, 2018 as the Group obtained the equity interest in Yunkang Industry through a series of contractual arrangements other than any cash considerations, which were considered as deemed contribution from the shareholders.

There were no movements in the Group's other reserves during six months ended June 30, 2022.

#### (b) Dividends

The Board declared an interim dividend for the six months ended June 30, 2022 of HK\$0.088 per Share on August 11, 2022. No dividends have been paid or declared by the Company during six months ended June 30, 2021.

### 21. 其他儲備及股息

#### (a) 其他儲備

本集團的其他儲備包括資本化儲備及按公平值計入其他全面收益的金融資產的儲備。

資本化儲備指截至2018年1月1日本公司擁有人應佔雲康健康產業投資股份有限公司(「雲康產業」)的資本及資本溢價合共約人民幣931百萬元，乃由於本集團透過一系列合約安排(任何現金代價除外)取得雲康產業的股權，被視為股東出資。

於截至2022年6月30日止六個月，本集團其他儲備概無任何變動。

#### (b) 股息

於2022年8月11日，董事會已宣派截至2022年6月30日止六個月中期股息每股0.088港元。截至2021年6月30日止六個月，本公司並無派付或宣派任何股息。

## Notes to the Interim Condensed Consolidated Financial Statements

### 中期簡明綜合財務報表附註

#### 22. COMMITMENTS

Significant capital expenditure contracted for at the end of the reporting period but not recognised as liabilities is as follows:

		As at June 30, 2022 於二零二二年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	As at December 31, 2021 於二零二一年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
<b>Contracted but not provided for:</b>	<b>已訂約但未撥備：</b>		
– Property and equipment	– 物業及設備	<b>339,036</b>	323,176

As at June 30, 2022, the Group's capital commitments mainly related to the construction of the land in Guangzhou acquired in 2019 and equipment procurements and decorations for the preparation of opening of new independent clinical laboratories.

#### 22. 承擔

於報告期末已訂約但未確認為負債的重大資本開支如下：

	As at June 30, 2022 於二零二二年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	As at December 31, 2021 於二零二一年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
<b>Contracted but not provided for:</b>		
– Property and equipment	<b>339,036</b>	323,176

於2022年6月30日，本集團的資本承擔主要與2019年於廣州收購土地的建設及為籌備新的獨立臨床實驗室開辦的設備採購及裝修有關。

#### 23. MATERIAL RELATED PARTY TRANSACTIONS

##### (a) Names and relationships with related parties

Related parties are those parties that have the ability to control, jointly control or exercise significant influence over the other party in holding power over the investee; exposure or rights, to variable returns from its involvement with the investee; and the ability to use its power over the investee to affect the amount of the investor's returns. Parties are also considered to be related if they are subject to common control or joint control. Related parties may be individuals or other entities.

#### 23. 重大關聯方交易

##### (a) 關聯方名稱及與關聯方的關係

關聯方指有能力控制、共同控制或對另一方在對投資對象的控制權上行使重大影響力的人士；因參與投資對象而承擔可變回報的風險或權利；及可利用其對投資對象的權力影響投資者回報金額的人士。倘各方受共同控制或聯合控制，亦被視為關聯方。關聯方可為個人或其他實體。

## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 23. MATERIAL RELATED PARTY TRANSACTIONS (Continued)

#### (a) Names and relationships with related parties (Continued)

Save as disclosed elsewhere in this report, the directors of the Company are of the view that the following parties/companies were related parties that had transactions or balances with the Group during six months ended June 30, 2022 and 2021.

#### Name of related parties

關聯方名稱

Mr. Zhang Yong  
張勇先生  
Da An Gene and its subsidiaries (“Da An Group”)  
達安基因及其附屬公司(「達安集團」)  
Zhuhai Hengqin Shiwei Kangjie Life Science  
Research Institute Co., Ltd. and its  
subsidiaries (“Shiwei Kangjie”)  
珠海橫琴世衛康傑生命科學研究院有限公司及  
其附屬公司(「世衛康傑」)

#### Relationship with the Group

與本集團的關係

The Controlling Shareholder of the Group  
本集團控股股東  
The shareholder with significant influence to the Group  
對本集團有重大影響的股東  
Controlled by Mr. Zhang Yong  
由張勇先生控制

#### (b) Key management compensation

### 23. 重大關聯方交易 (續)

#### (a) 關聯方名稱及與關聯方的關係 (續)

除本報告其他部分所披露者外，本公司董事認為，截至2022年及2021年6月30日止六個月與本集團有交易或結餘的關聯方／公司如下。

#### (b) 主要管理人員薪酬

For six months ended June 30,  
截至六月三十日止六個月

	2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Salaries, bonuses and other benefits in kind	2,464	1,998
Contribution to pension scheme expenses	226	104
	<b>2,690</b>	<b>2,102</b>



## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 23. MATERIAL RELATED PARTY TRANSACTIONS (Continued)

#### (c) Transactions with related parties

### 23. 重大關聯方交易 (續)

#### (c) 與關聯方的交易

For six months ended June 30,  
截至六月三十日止六個月

		2022 二零二二年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Revenue from – Da An Group	來自以下各方的收益 – 達安集團	2,260	796
Purchase of goods and services – Da An Group	購買商品及服務 – 達安集團	170,728	82,539
Lease of right-of-use assets – Da An Group	租賃使用權資產 – 達安集團	–	7,055
Interest expense paid/payable to related parties on lease liabilities – Da An Group	就租賃負債已付／ 應付關聯方的利息開支 – 達安集團	71	180
Commercial property management services fee to related parties – Da An Group	向關聯方支付的商業物業 管理服務費 – 達安集團	1,590	1,612

All of the transactions above were carried out in the normal course of the Group's business and on terms as agreed between the transacting parties.

上述所有交易均於本集團日常業務過程中按與交易方協定的條款進行。

**Notes to the Interim Condensed Consolidated Financial Statements**  
**中期簡明綜合財務報表附註**

**23. MATERIAL RELATED PARTY TRANSACTIONS (Continued)**

**(d) Balances with related parties**

**23. 重大關聯方交易 (續)**

**(d) 與關聯方的結餘**

		<b>As at June 30, 2022</b>	<b>As at December 31, 2021</b>
		於二零二二年 六月三十日	於二零二一年 十二月三十一日
		<b>RMB'000</b>	<b>RMB'000</b>
		人民幣千元	人民幣千元
		<b>(Unaudited)</b>	<b>(Audited)</b>
		(未經審核)	(經審核)
<b>Amount due from related parties</b>			
<b>Trade</b>			
Trade receivables			
– Da An Group	應收關聯方款項 貿易 貿易應收款項 – 達安集團	<b>325</b>	323
Other receivables	其他應收款項		
– Da An Group	– 達安集團	<b>1,436</b>	1,441
– Mr. Zhang Yong	– 張勇先生	<b>55</b>	29
		<b>1,491</b>	1,470
<b>Non-trade</b>			
Other receivables			
– Shiwei Kangjie	非貿易 其他應收款項 – 世衛康傑	–	19,750
			19,750
		<b>1,816</b>	21,543
<b>Amount due to related parties</b>			
<b>Trade</b>			
Trade payables			
– Da An Group	應付關聯方款項 貿易 貿易應付款項 – 達安集團	<b>(329,341)</b>	(192,175)
Other payables	其他應付款項		
– Da An Group	– 達安集團	<b>(11,528)</b>	(9,937)
		<b>(340,869)</b>	(202,112)
<b>Lease liabilities due to related parties</b>			
– Da An Group	應付關聯方租賃負債 – 達安集團	<b>(3,732)</b>	(3,661)

## Notes to the Interim Condensed Consolidated Financial Statements 中期簡明綜合財務報表附註

### 23. MATERIAL RELATED PARTY TRANSACTIONS (Continued)

#### (e) Guarantees from the related parties

		As at <b>June 30,</b> <b>2022</b> 於二零二二年 六月三十日 <b>RMB'000</b> 人民幣千元 <b>(Unaudited)</b> (未經審核)	As at December 31, 2021 於二零二一年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
<b>Guarantees provided by</b>	<b>由以下人士擔保</b>		
- Da An Group	- 達安集團	<b>39,000</b>	39,000

### 24. CONTINGENT LIABILITIES

As at June 30, 2022, the Group did not have any material contingent liabilities.

### 25. SUBSEQUENT EVENTS

Save as disclosed elsewhere in this report, no material subsequent events took place after June 30, 2022.

### 23. 重大關聯方交易 (續)

#### (e) 關聯方擔保

### 24. 或然負債

於2022年6月30日，本集團並無任何重大或然負債。

### 25. 期後事項

除本報告另有披露者外，於2022年6月30日後概無發生任何重大期後事項。



云康  
YUNKANG